WO1994029351A3 - Antibodies - Google Patents
Antibodies Download PDFInfo
- Publication number
- WO1994029351A3 WO1994029351A3 PCT/GB1994/001290 GB9401290W WO9429351A3 WO 1994029351 A3 WO1994029351 A3 WO 1994029351A3 GB 9401290 W GB9401290 W GB 9401290W WO 9429351 A3 WO9429351 A3 WO 9429351A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- provides
- modulating
- diagnosis
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94917750A EP0714409A1 (en) | 1993-06-16 | 1994-06-15 | Antibodies |
AU69341/94A AU691811B2 (en) | 1993-06-16 | 1994-06-15 | Antibodies |
JP7501518A JPH08511420A (en) | 1993-06-16 | 1994-06-15 | Body |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9312415.4 | 1993-06-16 | ||
GB939312415A GB9312415D0 (en) | 1993-06-16 | 1993-06-16 | Altered antibodies |
GB9401597A GB9401597D0 (en) | 1994-01-27 | 1994-01-27 | Altered antibodies |
GB9401597.1 | 1994-01-27 | ||
GB9402499.9 | 1994-02-09 | ||
GB9402499A GB9402499D0 (en) | 1994-02-09 | 1994-02-09 | Altered abtibodies |
GB9406244.5 | 1994-03-29 | ||
GB9406244A GB9406244D0 (en) | 1994-03-29 | 1994-03-29 | Altered antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994029351A2 WO1994029351A2 (en) | 1994-12-22 |
WO1994029351A3 true WO1994029351A3 (en) | 1994-12-22 |
Family
ID=27451034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1994/001290 WO1994029351A2 (en) | 1993-06-16 | 1994-06-15 | Antibodies |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0714409A1 (en) |
JP (1) | JPH08511420A (en) |
AU (1) | AU691811B2 (en) |
CA (1) | CA2163345A1 (en) |
WO (1) | WO1994029351A2 (en) |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US8039592B2 (en) | 2002-09-27 | 2011-10-18 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US8124731B2 (en) | 2002-03-01 | 2012-02-28 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
US8410250B2 (en) | 2009-03-25 | 2013-04-02 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8771966B2 (en) | 2010-06-03 | 2014-07-08 | Genentech, Inc. | Immuno-PET imaging of antibodies and immunoconjugates and uses therefor |
US8779100B2 (en) | 2004-09-03 | 2014-07-15 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8951517B2 (en) | 2003-01-09 | 2015-02-10 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US8957187B2 (en) | 2005-12-02 | 2015-02-17 | Genentech, Inc. | Binding polypeptides and uses thereof |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8969526B2 (en) | 2011-03-29 | 2015-03-03 | Roche Glycart Ag | Antibody Fc variants |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986686B2 (en) | 2002-06-14 | 2015-03-24 | Medimmune, Llc | Stabilized liquid anti-RSV antibody formulations |
US8993730B2 (en) | 2008-04-02 | 2015-03-31 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
US9011852B2 (en) | 2010-04-30 | 2015-04-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
US9040041B2 (en) | 2005-10-03 | 2015-05-26 | Xencor, Inc. | Modified FC molecules |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
US9107862B2 (en) | 2007-09-04 | 2015-08-18 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9133273B2 (en) | 2010-11-19 | 2015-09-15 | Eisai R&D Management Co., Ltd. | Nucleic acids encoding neutralizing anti-CCL20 antibodies |
US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9243069B2 (en) | 2008-04-02 | 2016-01-26 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using the same |
US9266961B2 (en) | 2012-06-15 | 2016-02-23 | Genentech, Inc. | Anti-PCSK9 antibodies, formulations, dosing, and methods of use |
US9266948B2 (en) | 2009-12-23 | 2016-02-23 | Genentech, Inc. | Anti-Bv8 antibodies and uses thereof |
US9283274B2 (en) | 2009-10-06 | 2016-03-15 | Medimmune Limited | RSV specific binding molecule |
US9428574B2 (en) | 2011-06-30 | 2016-08-30 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
US9441049B2 (en) | 2010-03-04 | 2016-09-13 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US9475881B2 (en) | 2010-01-19 | 2016-10-25 | Xencor, Inc. | Antibody variants with enhanced complement activity |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
EP4342529A2 (en) | 2015-12-18 | 2024-03-27 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
US11958903B2 (en) | 2019-03-29 | 2024-04-16 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
Families Citing this family (1082)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5985599A (en) * | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
CA2186455A1 (en) | 1994-03-29 | 1995-10-05 | Raymond John Owens | Antibodies against e-selectin |
US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
US7247302B1 (en) | 1996-08-02 | 2007-07-24 | Bristol-Myers Squibb Company | Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO1999032659A1 (en) * | 1997-12-22 | 1999-07-01 | Stiftelsen Universitetsforskning Bergen (Unifob) | METHOD FOR DISEASE PROGNOSIS BASED ON Fc RECEPTOR GENOTYPING |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
EP1068241B1 (en) * | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
GB9809951D0 (en) * | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CN1763097B (en) * | 1999-01-15 | 2011-04-13 | 杰南技术公司 | Polypeptide variants with altered effector function |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
JP2002540764A (en) | 1999-02-12 | 2002-12-03 | ジェネティックス・インスチチュート・インコーポレーテッド | Humanized immunoglobulin reacting with B7 molecule and therapeutic method using the same |
US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
BR0110610A (en) | 2000-04-11 | 2003-04-29 | Genentech Inc | Isolated antibodies, immunoconjugates, polypeptide chains, isolated nucleic acid, vector, host cell, antibody or polypeptide chain production process, method of treating mammalian dysfunction, method of inducing apoptosis of a cancer cell, method of killing a cell b, method for killing a cell expressing an erbb receptor and uses of isolated antibodies |
WO2001079299A1 (en) | 2000-04-13 | 2001-10-25 | The Rockefeller University | Enhancement of antibody-mediated immune responses |
US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
DK1283214T3 (en) | 2000-04-21 | 2007-06-11 | Fuso Pharmaceutical Ind | Hitherto unknown collectins |
WO2001093892A1 (en) | 2000-06-08 | 2001-12-13 | The Center For Blood Research, Inc. | Methods and compositions for inhibiting immunoglobulin-mediated__reperfusion injury |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
PT1355919E (en) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Molecules with extended half-lives, compositions and uses thereof |
US20030077739A1 (en) | 2001-08-27 | 2003-04-24 | Genentech, Inc. | System for antibody expression and assembly |
WO2003033538A1 (en) | 2001-10-15 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Anti-hla-dr antibody |
US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
US8530627B2 (en) | 2002-08-14 | 2013-09-10 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
AU2003300829A1 (en) * | 2002-12-06 | 2004-09-09 | Diadexus, Inc. | Compositions, splice variants and methods relating to lung specific genes and proteins |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
DE602004025332D1 (en) | 2003-03-14 | 2010-03-18 | Wyeth Corp | ANTIBODY TO IL21 RECEPTOR AND ITS USE |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
AU2008229860B2 (en) * | 2003-05-02 | 2012-01-12 | Xencor, Inc | Optimized Fc variants and methods for their generation |
NZ544923A (en) | 2003-06-27 | 2009-02-28 | Biogen Idec Inc | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous anti-body solutions |
CN1871259A (en) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | Improved antibodies having altered effector function and methods for making the same |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
EP2418220B1 (en) | 2003-12-10 | 2017-08-02 | E. R. Squibb & Sons, L.L.C. | Interferon alpha antibodies and their uses |
JP2007521248A (en) | 2003-12-10 | 2007-08-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | Humanized anti-CCR2 antibody and methods of using the antibody |
JP4942487B2 (en) | 2003-12-10 | 2012-05-30 | メダレックス インコーポレーティッド | IP-10 antibody and use thereof |
PT1718677E (en) | 2003-12-19 | 2012-07-18 | Genentech Inc | Monovalent antibody fragments useful as therapeutics |
PL1706424T3 (en) * | 2004-01-12 | 2010-04-30 | Mentrik Biotech Llc | Fc region variants |
DE602005026260D1 (en) | 2004-03-01 | 2011-03-24 | Immune Disease Inst Inc | NATURAL IGM ANTIBODIES AND INHIBITORS THEREOF |
BR122019012028B1 (en) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | ANTI-P-SELECTIN ANTIBODIES, NUCLEIC ACID MOLECULE, VECTOR, AND COMPOSITION |
MXPA06012601A (en) | 2004-05-10 | 2007-05-10 | Macrogenics Inc | HUMANIZED FcgammaRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF. |
WO2006002177A2 (en) | 2004-06-21 | 2006-01-05 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
WO2006033702A2 (en) | 2004-07-26 | 2006-03-30 | Biogen Idec Ma Inc. | Anti-cd154 antibodies |
JP5055603B2 (en) | 2004-08-04 | 2012-10-24 | メントリック・バイオテック・リミテッド・ライアビリティ・カンパニー | Mutated Fc region |
EP1773885B1 (en) | 2004-08-05 | 2010-04-21 | Genentech, Inc. | Humanized anti-cmet antagonists |
CA2577370A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
ES2557587T3 (en) | 2004-12-28 | 2016-01-27 | Innate Pharma | Monoclonal antibodies against NKG2A |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
WO2006089133A2 (en) | 2005-02-15 | 2006-08-24 | Duke University | Anti-cd19 antibodies and uses in oncology |
US7829673B2 (en) | 2005-03-23 | 2010-11-09 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
EP3479844B1 (en) | 2005-04-15 | 2023-11-22 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
CA2606102C (en) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
EP2221316A1 (en) | 2005-05-05 | 2010-08-25 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
CA2614181A1 (en) | 2005-07-01 | 2007-01-11 | Medimmune, Inc. | An integrated approach for generating multidomain protein therapeutics |
CN101248089A (en) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | Human monoclonal antibodies to programmed death ligand 1(PD-L1) |
US9580506B2 (en) | 2005-07-21 | 2017-02-28 | Genmab A/S | Potency assays for antibody drug substance binding to an Fc receptor |
SI1919503T1 (en) | 2005-08-10 | 2015-02-27 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
CA2625619A1 (en) | 2005-10-14 | 2007-04-26 | Medimmune, Inc. | Cell display of antibody libraries |
AR058104A1 (en) | 2005-10-21 | 2008-01-23 | Novartis Ag | ORGANIC COMPOUNDS |
ES2577292T3 (en) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Binding polypeptides with diversified VH / VL hypervariable sequences and consensus |
JP2009518314A (en) | 2005-12-02 | 2009-05-07 | ジェネンテック・インコーポレーテッド | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling comprising antibodies that bind IL-22 and antibodies that bind IL-22R |
CN101356195B (en) | 2005-12-08 | 2013-04-03 | 米德列斯公司 | Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 |
EP2325208B1 (en) | 2005-12-15 | 2017-09-20 | Genentech, Inc. | Polyubiquitin antibodies |
AU2007248444B2 (en) | 2006-01-05 | 2012-10-25 | Genentech, Inc. | Anti-EphB4 antibodies and methods using same |
HUE028179T2 (en) | 2006-01-12 | 2016-12-28 | Alexion Pharma Inc | Antibodies to OX-2/CD200 and uses thereof |
AR059096A1 (en) | 2006-01-20 | 2008-03-12 | Genentech Inc | ANTI-EFRINE ANTIBODIES -B2 AND METHODS USING THESE |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
TWI417301B (en) | 2006-02-21 | 2013-12-01 | Wyeth Corp | Antibodies against human il-22 and uses therefor |
EP2650306A1 (en) | 2006-03-06 | 2013-10-16 | Aeres Biomedical Limited | Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
AR059851A1 (en) | 2006-03-16 | 2008-04-30 | Genentech Inc | ANTIBODIES OF EGFL7 AND METHODS OF USE |
EP2343551B1 (en) | 2006-04-10 | 2014-05-28 | Genentech, Inc. | Dishevelled PDZ modulators |
WO2008105886A2 (en) | 2006-05-26 | 2008-09-04 | Macrogenics, Inc. | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
RU2436796C9 (en) | 2006-05-30 | 2013-12-27 | Дженентек, Инк. | Antibodies and immunoconjugates and their application |
EP2032604A2 (en) | 2006-06-06 | 2009-03-11 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
WO2008019199A2 (en) | 2006-06-26 | 2008-02-14 | Macrogenics, Inc. | FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
DK2383297T5 (en) | 2006-08-14 | 2022-07-04 | Xencor Inc | Optimized antibodies directed against CD19 |
KR20090088852A (en) | 2006-09-05 | 2009-08-20 | 메다렉스, 인코포레이티드 | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
AU2007294575B2 (en) | 2006-09-08 | 2013-06-27 | Viela Bio, Inc. | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
PL2066351T3 (en) | 2006-10-02 | 2016-02-29 | Squibb & Sons Llc | Human antibodies that bind cxcr4 and uses thereof |
CA2666682C (en) | 2006-10-19 | 2014-07-08 | Merck & Co., Inc. | Anti-il-13r.alpha.1 antibodies and their uses thereof |
ES2501947T3 (en) | 2006-10-19 | 2014-10-02 | Csl Limited | Interleukin alpha 1 receptor high affinity antibody antagonists |
KR101541550B1 (en) | 2006-10-27 | 2015-08-04 | 제넨테크, 인크. | Antibodies and immunoconjugates and uses therefor |
US8618248B2 (en) | 2006-10-31 | 2013-12-31 | President And Fellows Of Harvard College | Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides |
KR20170012582A (en) | 2006-11-02 | 2017-02-02 | 악셀레론 파마 인코포레이티드 | Alk1 receptor and ligand antagonists and uses thereof |
CL2007003291A1 (en) | 2006-11-15 | 2008-07-04 | Medarex Inc | ISOLATED HUMAN MONOCLONAL ANTIBODY THAT LINKS THE BTLA PROTEIN OR FRAGMENTS OF THE SAME; NUCLEIC ACID THAT CODIFIES IT; METHOD OF PRODUCTION; COMPOSITION AND IMMUNOCUJUGADO THAT UNDERSTANDS THEM; AND METHOD TO INHIBIT THE GROWTH OF TUMOR CELLS AND |
NZ578064A (en) | 2006-12-01 | 2012-01-12 | Medarex Inc | Human antibodies that bind cd22 and uses thereof |
US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
CL2007003622A1 (en) | 2006-12-13 | 2009-08-07 | Medarex Inc | Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method. |
KR20090088946A (en) | 2006-12-14 | 2009-08-20 | 메다렉스, 인코포레이티드 | Human antibodies that bind cd70 and uses thereof |
RU2009133784A (en) | 2007-02-09 | 2011-03-20 | Дженентек, Инк. (Us) | ANTI-Robo4-ANTIBODIES AND THEIR APPLICATIONS |
CN103214577B (en) | 2007-03-22 | 2015-09-02 | 生物基因Ma公司 | Specific binding CD154 comprises associated proteins of antibody, antibody derivatives and antibody fragment and uses thereof |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
SI2644205T1 (en) | 2007-04-12 | 2018-11-30 | The Brigham And Women's Hospital, Inc. | Targeting ABCB5 for cancer therapy |
RU2549701C2 (en) | 2007-05-07 | 2015-04-27 | Медиммун, Ллк | Anti-icos antibodies and their application in treatment of oncological, transplantation-associated and autoimmune diseases |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
PE20090321A1 (en) | 2007-06-04 | 2009-04-20 | Genentech Inc | ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION |
CA2683791A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains & antagonists |
US20090155275A1 (en) | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
BRPI0815399A2 (en) | 2007-08-13 | 2019-09-24 | Vasgene Therapeutics Inc | cancer treatment using humanized antibodies that bind ephb4 |
EP3415529B1 (en) | 2007-09-26 | 2020-11-04 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
AR068767A1 (en) | 2007-10-12 | 2009-12-02 | Novartis Ag | ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN |
AU2008320823B2 (en) | 2007-11-02 | 2013-01-17 | Novartis Ag | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) |
AU2008323770B2 (en) | 2007-11-07 | 2014-08-07 | Genentech, Inc. | Compositions and methods for treatment of microbial disorders |
WO2015164330A1 (en) | 2014-04-21 | 2015-10-29 | Millennium Pharmaceuticals, Inc. | Anti-psyk antibody molecules and use of same for syk-targeted therapy |
TWI580694B (en) | 2007-11-30 | 2017-05-01 | 建南德克公司 | Anti-vegf antibodies |
DK2222706T4 (en) | 2007-12-14 | 2016-11-21 | Novo Nordisk As | Antibodies that bind to NKG2D and its use |
US8795667B2 (en) | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
WO2009081201A2 (en) | 2007-12-21 | 2009-07-02 | Medimmune Limited | BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Rα) - 173 |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
ES2742268T3 (en) | 2007-12-26 | 2020-02-13 | Xencor Inc | Fc variants with altered FcRn binding |
CA2711771C (en) | 2008-01-11 | 2017-01-24 | Gene Techno Science Co., Ltd. | Humanized anti-.alpha.9 integrin antibodies and the uses thereof |
WO2009100110A1 (en) | 2008-02-05 | 2009-08-13 | Medarex, Inc. | Alpha 5 - beta 1 antibodies and their uses |
PT2250279E (en) * | 2008-02-08 | 2016-06-03 | Medimmune Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
WO2009131256A1 (en) | 2008-04-24 | 2009-10-29 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof |
EP2283040A2 (en) | 2008-05-02 | 2011-02-16 | Acceleron Pharma, Inc. | Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage |
US8680020B2 (en) | 2008-07-15 | 2014-03-25 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated glass slides and related methods |
US9182406B2 (en) | 2008-08-04 | 2015-11-10 | Biodesy, Inc. | Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability |
NZ590634A (en) | 2008-08-05 | 2012-07-27 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
AU2009294415B2 (en) | 2008-09-19 | 2015-09-24 | Medimmune Llc | Antibodies directed to DLL4 and uses thereof |
US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
ES2719496T3 (en) | 2008-11-12 | 2019-07-10 | Medimmune Llc | Antibody formulation |
EP2364326B1 (en) | 2008-12-05 | 2018-07-04 | Glaxo Group Limited | Methods for selecting protease resistant polypeptides |
EP2373690B1 (en) | 2008-12-08 | 2015-02-11 | Compugen Ltd. | Antibodies specific for tmem154 |
WO2010068722A1 (en) | 2008-12-12 | 2010-06-17 | Medimmune, Llc | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
JP2012513194A (en) | 2008-12-23 | 2012-06-14 | アストラゼネカ アクチボラグ | Targeted binding agents directed to α5β1 and uses thereof |
US20110301335A1 (en) | 2009-02-19 | 2011-12-08 | Stephen Duffield | Anti-tnfr1 polypeptides, antibody variable domains & antagonists |
JP2012518404A (en) | 2009-02-23 | 2012-08-16 | グレンマーク・ファーマシューティカルズ・エスエー | Humanized antibodies that bind to CD19 and uses thereof |
BRPI1009232B1 (en) | 2009-03-05 | 2022-05-03 | E.R. Squibb & Sons, Llc. | Isolated monoclonal antibody or an antigen-binding portion thereof, or an antibody fragment, composition comprising them, nucleic acid molecule, hybridoma and methods for preparing an anti-cadm1 antibody |
MX2011009729A (en) | 2009-03-20 | 2011-10-14 | Genentech Inc | Bispecific anti-her antibodies. |
TWI504409B (en) | 2009-03-25 | 2015-10-21 | Genentech Inc | Novel anti-α5β1 antibodies and uses thereof |
SG10201401604VA (en) | 2009-04-20 | 2014-08-28 | Oxford Biotherapeutics Ltd | Antibodies Specific To Cadherin-17 |
WO2010124113A1 (en) | 2009-04-23 | 2010-10-28 | Infinity Pharmaceuticals, Inc. | Anti-fatty acid amide hydrolase-2 antibodies and uses thereof |
AR076402A1 (en) | 2009-04-27 | 2011-06-08 | Novartis Ag | COMPOSITIONS AND METHODS TO INCREASE MUSCLE GROWTH |
EA201101572A1 (en) | 2009-04-27 | 2012-05-30 | Новартис Аг | COMPOSITIONS AND METHODS OF APPLICATION OF THERAPEUTIC ANTIBODIES SPECIFIC TO THE SUB-UNIT OF BETA1 IL-12 RECEPTOR |
SG176060A1 (en) | 2009-05-13 | 2011-12-29 | Genzyme Corp | Anti-human cd52 immunoglobulins |
EP2995315B1 (en) | 2009-05-15 | 2023-12-27 | University Health Network | Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US9090690B2 (en) | 2009-06-18 | 2015-07-28 | Pfizer Inc. | Anti Notch-1 antibodies |
WO2011006914A2 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Antagonists, uses & methods for partially inhibiting tnfr1 |
WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
SG177689A1 (en) | 2009-07-31 | 2012-02-28 | Organon Nv | Fully human antibodies to btla |
WO2011021146A1 (en) | 2009-08-20 | 2011-02-24 | Pfizer Inc. | Osteopontin antibodies |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011029823A1 (en) | 2009-09-09 | 2011-03-17 | Novartis Ag | Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells |
WO2011047083A1 (en) | 2009-10-13 | 2011-04-21 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
US8759491B2 (en) | 2009-10-19 | 2014-06-24 | Genentech, Inc. | Modulators of hepatocyte growth factor activator |
CA2778481A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Anti-hepsin antibodies and methods using same |
CA3031851C (en) | 2009-10-23 | 2020-07-07 | Amgen British Columbia | Anti-gcc antibody molecules and related compositions and methods |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
JP2013507978A (en) | 2009-10-27 | 2013-03-07 | グラクソ グループ リミテッド | Stable anti-TNFR1 polypeptides, antibody variable domains and antagonists |
JO3437B1 (en) | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | Improved anti human Fraktalkine antibodies and uses thereof |
MX2012005180A (en) | 2009-11-04 | 2012-06-08 | Merck Sharp & Dohme | Engineered anti-tslp antibody. |
EP2496601B1 (en) | 2009-11-05 | 2017-06-07 | F. Hoffmann-La Roche AG | Methods and composition for secretion of heterologous polypeptides |
NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
US9428586B2 (en) | 2009-12-01 | 2016-08-30 | Compugen Ltd | Heparanase splice variant |
US8722615B2 (en) | 2009-12-02 | 2014-05-13 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
TWI505836B (en) | 2009-12-11 | 2015-11-01 | Genentech Inc | Anti-vegf-c antibodies and methods using same |
AU2010334974A1 (en) | 2009-12-22 | 2012-07-12 | Novartis Ag | Tetravalent CD47-antibody constant region fusion protein for use in therapy |
EA027502B1 (en) * | 2009-12-23 | 2017-08-31 | Зиниммуне Гмбх | Anti-flt3 antibodies and methods of using the same |
RU2012134369A (en) | 2010-01-11 | 2014-02-20 | Алексион Фармасьютикалз, Инк | BIOMARKERS OF IMMUNOMODULATING EFFECTS IN PEOPLE EXPOSED TO ANTIMETAL TREATMENT AGAINST CD200 |
MX2012009318A (en) | 2010-02-10 | 2012-09-07 | Novartis Ag | Methods and compounds for muscle growth. |
CA2789629A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc. | Cd20 antibodies and uses thereof |
JP5981853B2 (en) | 2010-02-18 | 2016-08-31 | ジェネンテック, インコーポレイテッド | Neuregulin antagonists and their use in the treatment of cancer |
WO2011101328A2 (en) | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
JP5778700B2 (en) | 2010-02-24 | 2015-09-16 | イミュノジェン, インコーポレイテッド | Folate receptor 1 antibody and immunoconjugate and use thereof |
KR101899835B1 (en) | 2010-03-24 | 2018-09-19 | 제넨테크, 인크. | Anti-lrp6 antibodies |
WO2011120013A2 (en) | 2010-03-26 | 2011-09-29 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
NZ603829A (en) | 2010-05-06 | 2015-03-27 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies |
EP2566894A1 (en) | 2010-05-06 | 2013-03-13 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
CA2794731C (en) | 2010-06-18 | 2019-03-19 | Genentech, Inc. | Anti-axl antibodies and methods of use |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
MX2012014975A (en) | 2010-06-22 | 2013-03-12 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3. |
WO2011161189A1 (en) | 2010-06-24 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods of use |
SG186983A1 (en) | 2010-07-09 | 2013-02-28 | Genentech Inc | Anti-neuropilin antibodies and methods of use |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
SG187682A1 (en) | 2010-08-02 | 2013-03-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
KR20130045914A (en) | 2010-08-03 | 2013-05-06 | 에프. 호프만-라 로슈 아게 | Chronic lymphocytic leukemia (cll) biomarkers |
RU2013106217A (en) | 2010-08-05 | 2014-09-10 | Ф. Хоффманн-Ля Рош Аг | HYBRID PROTEIN FROM ANTIBODIES AGAINST MHC AND ANTIVIRAL CYTOKINE |
RU2584597C2 (en) | 2010-08-13 | 2016-05-20 | Рош Гликарт Аг | Antibodies against a2 tenastin-c and methods for use thereof |
SI2603530T1 (en) | 2010-08-13 | 2018-02-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
US20130177555A1 (en) | 2010-08-13 | 2013-07-11 | Medimmune Limited | Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
MY162825A (en) | 2010-08-20 | 2017-07-31 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
KR101603001B1 (en) | 2010-08-25 | 2016-03-11 | 에프. 호프만-라 로슈 아게 | Antibodies against il-18r1 and uses thereof |
BR112013004673A8 (en) | 2010-08-31 | 2018-01-02 | Genentech Inc | biomarkers and treatment methods. |
WO2012035518A1 (en) | 2010-09-17 | 2012-03-22 | Compugen Ltd. | Compositions and methods for treatment of drug resistant multiple myeloma |
EP2625203A1 (en) | 2010-10-05 | 2013-08-14 | Novartis AG | Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders |
WO2012047968A2 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
EP2638070B1 (en) | 2010-11-10 | 2016-10-19 | F.Hoffmann-La Roche Ag | Methods and compositions for neural disease immunotherapy |
CA2818635C (en) | 2010-12-06 | 2021-06-15 | National Reseach Council Of Canada | Antibodies selective for cells presenting erbb2 at high density |
CA2821130C (en) | 2010-12-15 | 2017-11-07 | Wyeth Llc | Anti-notch1 antibodies |
AU2011343570B2 (en) | 2010-12-16 | 2016-11-03 | Genentech, Inc. | Diagnosis and treatments relating to TH2 inhibition |
NZ610976A (en) | 2010-12-20 | 2015-07-31 | Genentech Inc | Anti-mesothelin antibodies and immunoconjugates |
JP2014511106A (en) | 2010-12-22 | 2014-05-08 | ジェネンテック, インコーポレイテッド | Anti-PCSK9 antibody and method of use |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
ES2860748T3 (en) | 2011-01-24 | 2021-10-05 | Gilead Sciences Inc | Selective Antibodies for EGFR-Presenting Cells with High Density |
JP6150734B2 (en) | 2011-02-03 | 2017-06-21 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Use of anti-CD200 antibodies to prolong allograft survival |
BR112013020338A2 (en) | 2011-02-28 | 2016-10-18 | Hoffmann La Roche | monovalent antigen binding protein, pharmaceutical composition, use of monovalent antigen binding protein, method for treating a patient in need of therapy, method for preparing a monovalent antigen binding protein, nucleic acid, vector and cell hostess |
EP2681239B8 (en) | 2011-02-28 | 2015-09-09 | F. Hoffmann-La Roche AG | Antigen binding proteins |
AU2012230899A1 (en) | 2011-03-21 | 2013-10-10 | Biodesy, Llc | Classification of kinase inhibitors using nonlinear optical techniques |
SI2694106T1 (en) | 2011-04-01 | 2018-04-30 | Immunogen, Inc. | Methods for increasing efficacy of folr1 cancer therapy |
EP2694551A1 (en) | 2011-04-07 | 2014-02-12 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
ES2942455T3 (en) | 2011-04-13 | 2023-06-01 | Bristol Myers Squibb Co | Fc fusion proteins comprising novel linkers or arrangements |
WO2012140627A1 (en) | 2011-04-15 | 2012-10-18 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
AU2012245439B2 (en) | 2011-04-20 | 2017-04-06 | Acceleron Pharma, Inc. | Endoglin polypeptides and uses thereof |
WO2012146630A1 (en) | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | N-terminal acylated polypeptides, methods for their production and uses thereof |
PE20141672A1 (en) | 2011-05-02 | 2014-11-26 | Millennium Pharm Inc | FORMULATION FOR ANTI-alpha4�7 ANTIBODY |
UA116189C2 (en) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
EP2707723B1 (en) | 2011-05-12 | 2016-02-10 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
EP2707391B1 (en) | 2011-05-13 | 2017-11-08 | Gamamabs Pharma | Antibodies against her3 |
AU2012255881C1 (en) | 2011-05-16 | 2015-11-26 | Genentech, Inc. | FGFR1 agonists and methods of use |
US9376495B2 (en) | 2011-05-21 | 2016-06-28 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use in extending serum half-life |
CA2837169C (en) | 2011-05-24 | 2021-11-09 | Zyngenia, Inc. | Multispecific complexes comprising angiopoietin-2-binding peptide and their uses |
WO2012172495A1 (en) | 2011-06-14 | 2012-12-20 | Novartis Ag | Compositions and methods for antibodies targeting tem8 |
EP2721067B1 (en) | 2011-06-15 | 2019-07-31 | F.Hoffmann-La Roche Ag | Anti-human epo receptor antibodies and methods of use |
US20140193408A1 (en) | 2011-06-16 | 2014-07-10 | Novartis Ag | Soluble proteins for use as therapeutics |
EP2723377B1 (en) | 2011-06-22 | 2018-06-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
WO2012175691A1 (en) | 2011-06-22 | 2012-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
AR086982A1 (en) | 2011-06-22 | 2014-02-05 | Hoffmann La Roche | ELIMINATION OF DIANA CELLS BY SPECIFIC CYTOTOXIC T-CELLS OF VIRUSES USING COMPLEXES THAT INCLUDE MHC CLASS I |
NZ618503A (en) | 2011-06-28 | 2016-03-31 | Oxford Biotherapeutics Ltd | Antibodies to adp-ribosyl cyclase 2 |
AR086823A1 (en) | 2011-06-30 | 2014-01-22 | Genentech Inc | ANTI-C-MET ANTIBODY FORMULATIONS, METHODS |
HUE040276T2 (en) | 2011-07-01 | 2019-02-28 | Novartis Ag | Method for treating metabolic disorders |
AU2012282116B2 (en) | 2011-07-11 | 2016-07-07 | Ichnos Sciences SA | Antibodies that bind to OX40 and their uses |
US9238689B2 (en) | 2011-07-15 | 2016-01-19 | Morpho Sys AG | Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT) |
CA2842375A1 (en) | 2011-08-17 | 2013-02-21 | Erica Jackson | Neuregulin antibodies and uses thereof |
KR20140048292A (en) | 2011-08-23 | 2014-04-23 | 로슈 글리카트 아게 | Anti-mcsp antibodies |
BR112014005720A2 (en) | 2011-09-15 | 2017-12-12 | Genentech Inc | method of selecting and / or identifying a usp1 antagonist, uaf1 antagonist and / or an id antagonist that promotes a change in the cellular fate of said method |
RU2014114617A (en) | 2011-09-19 | 2015-10-27 | Дженентек, Инк. | COMBINED TREATMENTS CONTAINING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS |
PE20142361A1 (en) | 2011-09-30 | 2015-01-16 | Dana Farber Cancer Inst Inc | THERAPEUTIC PEPTIDES |
AU2012319150B2 (en) | 2011-10-05 | 2017-08-17 | Genentech, Inc. | Methods of treating liver conditions using Notch2 antagonists |
JP6190813B2 (en) | 2011-10-14 | 2017-08-30 | ジェネンテック, インコーポレイテッド | Zymogen activator |
ES2769786T3 (en) | 2011-10-14 | 2020-06-29 | Recordati Ag | Antibodies and methods for diseases related to the Wnt pathway |
RS57645B1 (en) | 2011-10-14 | 2018-11-30 | Hoffmann La Roche | Anti-htra1 antibodies and methods of use |
RU2014119426A (en) | 2011-10-15 | 2015-11-20 | Дженентек, Инк. | WAYS OF APPLICATION OF SCD1 ANTAGONISTS |
WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
SG11201401815XA (en) | 2011-10-28 | 2014-05-29 | Genentech Inc | Therapeutic combinations and methods of treating melanoma |
CA2854806A1 (en) | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
TW201326193A (en) | 2011-11-21 | 2013-07-01 | Genentech Inc | Purification of anti-c-met antibodies |
CN104159924B (en) | 2011-12-05 | 2018-03-16 | 诺华股份有限公司 | The antibody of EGF-R ELISA 3 (HER3) |
EA201491107A1 (en) | 2011-12-05 | 2014-11-28 | Новартис Аг | ANTIBODIES TO THE RECEPTOR EPIDERMAL GROWTH FACTOR 3 (HER3), DIRECTED TO DOMAIN II HER3 |
EP2788024A1 (en) | 2011-12-06 | 2014-10-15 | F.Hoffmann-La Roche Ag | Antibody formulation |
RU2685867C2 (en) | 2011-12-15 | 2019-04-23 | Алтернатив Инновейтив Текнолоджиз Ллц | Hybrid proteins and protein conjugates based on heat shock protein-70 (hsp70) and methods for use thereof (versions) |
EP2794656B1 (en) | 2011-12-21 | 2019-02-27 | Novartis AG | Compositions comprising antibodies targeting factor p and c5 |
WO2013096791A1 (en) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Process for making high concentration protein formulations |
AU2013208007A1 (en) | 2012-01-09 | 2014-07-31 | The Scripps Research Institute | Humanized antibodies with ultralong CDR3 |
JP6684490B2 (en) | 2012-01-09 | 2020-04-22 | ザ・スクリップス・リサーチ・インスティテュート | Ultralong complementarity determining regions and uses thereof |
WO2013109856A2 (en) | 2012-01-18 | 2013-07-25 | Genentech, Inc. | Methods of using fgf19 modulators |
PE20141561A1 (en) | 2012-01-18 | 2014-11-12 | Genentech Inc | ANTI-LRP5 ANTIBODIES AND METHODS OF USE |
SG2014008304A (en) | 2012-02-01 | 2014-06-27 | Compugen Ltd | C10rf32 antibodies, and uses thereof for treatment of cancer |
EP2812350B1 (en) | 2012-02-11 | 2019-04-03 | F.Hoffmann-La Roche Ag | R-spondin translocations and methods using the same |
BR112014018005B1 (en) | 2012-02-15 | 2021-06-29 | F. Hoffmann-La Roche Ag | USE OF A NON-COVALENT IMMOBILIZED COMPLEX |
WO2013137920A1 (en) | 2012-03-16 | 2013-09-19 | Genentech, Inc. | Engineered conformationally-stabilized proteins |
US9139863B2 (en) | 2012-03-16 | 2015-09-22 | Genentech, Inc. | Engineered conformationally-stabilized proteins |
US20130259867A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
AR090549A1 (en) | 2012-03-30 | 2014-11-19 | Genentech Inc | ANTI-LGR5 AND IMMUNOCATE PLAYERS |
MX356800B (en) | 2012-04-05 | 2018-06-13 | Ac Immune Sa | Humanized tau antibody. |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
EP2841951B1 (en) | 2012-04-25 | 2019-12-11 | Biodesy, Inc. | Methods for detecting allosteric modulators of proteins |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
TW201402609A (en) | 2012-05-01 | 2014-01-16 | Genentech Inc | Anti-PMEL17 antibodies and immunoconjugates |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
JP6294311B2 (en) | 2012-05-23 | 2018-03-14 | ジェネンテック, インコーポレイテッド | How to select a treatment |
CN104334576B (en) | 2012-06-04 | 2019-02-19 | 诺华股份有限公司 | Site-specific labeling's method and resulting molecule |
ES2666126T3 (en) | 2012-06-08 | 2018-05-03 | Glenmark Pharmaceuticals S.A. | Humanized anti-TrkA antibodies with amino acid substitutions |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
EP2869848B1 (en) | 2012-07-04 | 2016-09-21 | F. Hoffmann-La Roche AG | Covalently linked antigen-antibody conjugates |
CN107082810B (en) | 2012-07-04 | 2020-12-25 | 弗·哈夫曼-拉罗切有限公司 | Anti-theophylline antibodies and methods of use |
WO2014006123A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Anti-biotin antibodies and methods of use |
SI2870247T1 (en) | 2012-07-05 | 2019-10-30 | Hoffmann La Roche | Expression and secretion system |
AU2013288929A1 (en) | 2012-07-09 | 2014-12-04 | Genentech, Inc. | Immunoconjugates comprising anti-CD22 antibodies |
EA201590171A1 (en) | 2012-07-09 | 2015-09-30 | Дженентек, Инк. | IMMUNOCONGATES CONTAINING ANTIBODIES TO CD79b |
SG11201500096YA (en) | 2012-07-09 | 2015-02-27 | Genentech Inc | Immunoconjugates comprising anti - cd79b antibodies |
WO2014011520A1 (en) | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
LT2872534T (en) | 2012-07-13 | 2018-10-25 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
NZ630363A (en) | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
DK2880170T3 (en) | 2012-08-02 | 2016-10-24 | Hoffmann La Roche | PROCEDURE FOR PREPARING SOLUBLE FcR AS Fc FUSION WITH INERT IMMUNOGLOBULIN Fc REGION AND APPLICATIONS THEREOF |
JP6302909B2 (en) | 2012-08-18 | 2018-03-28 | アカデミア シニカAcademia Sinica | Cell-permeable probes for sialidase identification and imaging |
CA3137438A1 (en) | 2012-08-31 | 2014-03-06 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
JOP20200308A1 (en) | 2012-09-07 | 2017-06-16 | Novartis Ag | IL-18 binding molecules |
CN109793893B (en) | 2012-09-07 | 2023-05-26 | 达特茅斯大学理事会 | VISTA modulators for diagnosis and treatment of cancer |
AU2013337277B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel NTRK1 fusion molecules and uses thereof |
WO2014072306A1 (en) | 2012-11-08 | 2014-05-15 | F. Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
TWI657095B (en) | 2012-11-13 | 2019-04-21 | 美商建南德克公司 | Anti-hemagglutinin antibodies and methods of use |
EP2733153A1 (en) | 2012-11-15 | 2014-05-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the preparation of immunoconjugates and uses thereof |
WO2014084859A1 (en) | 2012-11-30 | 2014-06-05 | Novartis Ag | Molecules and methods for modulating tmem16a activities |
MX368067B (en) | 2012-12-05 | 2019-09-18 | Novartis Ag | Compositions and methods for antibodies targeting epo. |
PT2928923T (en) | 2012-12-10 | 2020-03-27 | Biogen Ma Inc | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
PL2931752T3 (en) | 2012-12-17 | 2020-02-28 | Trillium Therapeutics Inc. | Treatment of cd47+ disease cells with sirp alpha-fc fusions |
WO2014096015A1 (en) | 2012-12-21 | 2014-06-26 | F. Hoffmann-La Roche Ag | Disulfide-linked multivalent mhc class i comprising multi-function proteins |
CN105102067B (en) | 2013-01-02 | 2020-03-03 | 艾科诺斯科技股份有限公司 | Antibodies that bind TL1A and uses thereof |
WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
EP3939614A1 (en) | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
PT2953976T (en) | 2013-02-08 | 2021-06-23 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
PT2953969T (en) | 2013-02-08 | 2019-12-03 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
EP3299378B1 (en) | 2013-02-12 | 2019-07-31 | Bristol-Myers Squibb Company | High ph protein refolding methods |
WO2014126871A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
KR20150118159A (en) | 2013-02-22 | 2015-10-21 | 에프. 호프만-라 로슈 아게 | Methods of treating cancer and preventing drug resistance |
CN104936987A (en) | 2013-02-26 | 2015-09-23 | 罗切格利卡特公司 | Anti-MCSP antibodies |
US9925240B2 (en) | 2013-03-06 | 2018-03-27 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
EP3299391B1 (en) | 2013-03-14 | 2019-12-04 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
MX2015011606A (en) | 2013-03-14 | 2016-05-17 | Genentech Inc | Methods of treating cancer and preventing cancer drug resistance. |
EP2970479B1 (en) | 2013-03-14 | 2019-04-24 | Novartis AG | Antibodies against notch 3 |
SI2968520T1 (en) | 2013-03-14 | 2022-01-31 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
JP2016515132A (en) | 2013-03-14 | 2016-05-26 | ジェネンテック, インコーポレイテッド | Combination and use of MEK inhibitor compounds with HER3 / EGFR inhibitor compounds |
EP3514178A1 (en) | 2013-03-15 | 2019-07-24 | Novartis AG | Antibody drug conjugates |
WO2014150877A2 (en) | 2013-03-15 | 2014-09-25 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
JP6527132B2 (en) | 2013-03-15 | 2019-06-05 | ジェネンテック, インコーポレイテッド | Compositions and methods for diagnosis and treatment of liver cancer |
EA201591559A1 (en) | 2013-03-15 | 2016-03-31 | Дана-Фарбер Кэнсер Инститьют, Инк. | THERAPEUTIC PEPTIDES |
AU2014235453A1 (en) | 2013-03-15 | 2015-10-08 | Genentech, Inc. | Biomarkers and methods of treating PD-1 and PD-L1 related conditions |
WO2014143739A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
MX368005B (en) | 2013-03-15 | 2019-09-13 | Genentech Inc | Il-22 polypeptides and il-22 fc fusion proteins and methods of use. |
WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
MX2015011899A (en) | 2013-03-15 | 2016-05-05 | Genentech Inc | Methods of treating cancer and preventing cancer drug resistance. |
JP2016517441A (en) | 2013-03-15 | 2016-06-16 | ジェネンテック, インコーポレイテッド | Anti-CRTh2 antibody and method of use |
AR095199A1 (en) | 2013-03-15 | 2015-09-30 | Genzyme Corp | ANTI-CD52 ANTIBODIES |
CN105392801A (en) | 2013-03-15 | 2016-03-09 | 比奥根Ma公司 | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
AU2014261631B2 (en) | 2013-04-29 | 2019-02-14 | F. Hoffmann-La Roche Ag | FcRn-binding abolished anti-IGF-1R antibodies and their use in the treatment of vascular eye diseases |
AU2014261630B2 (en) | 2013-04-29 | 2019-05-09 | F. Hoffmann-La Roche Ag | Human FcRn-binding modified antibodies and methods of use |
EP2992010B1 (en) | 2013-04-29 | 2021-03-24 | F.Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
KR102293064B1 (en) | 2013-05-20 | 2021-08-23 | 제넨테크, 인크. | Anti-transferrin receptor antibodies and methods of use |
US20160115237A1 (en) | 2013-05-24 | 2016-04-28 | The University Of British Columbia | Cell senescence markers as diagnostic and therapeutic targets |
UY35620A (en) | 2013-06-21 | 2015-01-30 | Novartis Ag | ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE |
AR096601A1 (en) | 2013-06-21 | 2016-01-20 | Novartis Ag | ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE |
WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
WO2015010100A2 (en) | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Humanized antibodies with ultralong complementarity determining regions |
WO2015017146A2 (en) | 2013-07-18 | 2015-02-05 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
UA116479C2 (en) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof |
TN2016000057A1 (en) | 2013-08-14 | 2017-07-05 | Novartis Ag | Methods of treating sporadic inclusion body myositis |
AU2014308751B2 (en) | 2013-08-22 | 2020-03-05 | Acceleron Pharma, Inc. | TGF-beta receptor type II variants and uses thereof |
EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
IL293871A (en) | 2013-08-30 | 2022-08-01 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
CN105682666B (en) | 2013-09-06 | 2021-06-01 | 中央研究院 | Activation of human iNKT cells using glycolipids |
EP4130044A1 (en) | 2013-09-13 | 2023-02-08 | BeiGene Switzerland GmbH | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
CN105518027A (en) | 2013-09-17 | 2016-04-20 | 豪夫迈·罗氏有限公司 | Methods of using anti-LGR5 antibodies |
PT3050896T (en) | 2013-09-27 | 2021-08-24 | Chugai Pharmaceutical Co Ltd | Method for producing polypeptide heteromultimer |
LT3052192T (en) | 2013-10-02 | 2020-12-10 | Medimmune, Llc | Neutralizing anti-influenza a antibodies and uses thereof |
EP3055328A1 (en) | 2013-10-11 | 2016-08-17 | F. Hoffmann-La Roche AG | Nsp4 inhibitors and methods of use |
CA2922912A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
WO2015057939A1 (en) | 2013-10-18 | 2015-04-23 | Biogen Idec Ma Inc. | Anti-s1p4 antibodies and uses thereof |
CA2925598A1 (en) | 2013-10-18 | 2015-04-23 | Genentech, Inc. | Anti-rspo antibodies and methods of use |
SG11201603127WA (en) | 2013-10-23 | 2016-05-30 | Genentech Inc | Methods of diagnosing and treating eosinophilic disorders |
WO2015061666A1 (en) | 2013-10-25 | 2015-04-30 | Acceleron Pharma, Inc. | Endoglin peptides to treat fibrotic diseases |
US10196455B2 (en) | 2013-11-07 | 2019-02-05 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Neuregulin allosteric anti-HER3 antibody |
CN104623637A (en) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Application of IL-22 dimer in preparation of intravenous injection drugs |
MX2016005631A (en) | 2013-11-21 | 2016-07-14 | Hoffmann La Roche | ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE. |
EP3077504B1 (en) | 2013-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
AU2014363944B2 (en) | 2013-12-09 | 2020-03-26 | Allakos Inc. | Anti-Siglec-8 antibodies and methods of use thereof |
EP3080164B1 (en) | 2013-12-13 | 2019-01-16 | Genentech, Inc. | Anti-cd33 antibodies and immunoconjugates |
RU2016128726A (en) | 2013-12-17 | 2018-01-23 | Дженентек, Инк. | METHODS FOR TREATING MALIGNANT TUMORS USING PD-1 BINDING ANTAGONISTS AND ANTIBODIES AGAINST CD20 |
HUE050156T2 (en) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-cd3 antibodies and methods of use |
US20150190506A1 (en) | 2013-12-17 | 2015-07-09 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
MX2016007972A (en) | 2013-12-17 | 2016-10-28 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes. |
PT3083680T (en) | 2013-12-20 | 2020-03-17 | Hoffmann La Roche | Humanized anti-tau(ps422) antibodies and methods of use |
TWI728373B (en) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | Antibodies and methods of use |
ES2742682T3 (en) | 2013-12-24 | 2020-02-17 | Argenx Bvba | FCRN antagonists and methods of use |
CA2935378C (en) | 2013-12-24 | 2023-04-18 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
CN105873616B (en) | 2014-01-03 | 2020-06-05 | 豪夫迈·罗氏有限公司 | Covalently linked polypeptide toxin-antibody conjugates |
JP6476194B2 (en) | 2014-01-03 | 2019-02-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Bispecific anti-hapten / anti-blood brain barrier receptor antibodies, complexes thereof, and their use as blood brain barrier shuttles |
RU2694981C2 (en) | 2014-01-03 | 2019-07-18 | Ф. Хоффманн-Ля Рош Аг | Covalently linked conjugates chelicar-antibody against chelicar and use thereof |
RU2694659C2 (en) | 2014-01-06 | 2019-07-16 | Ф. Хоффманн-Ля Рош Аг | Monovalent carrier modules across blood-brain barrier |
RU2727639C2 (en) | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Variants of fc-region with modified ability to bind to fcrn and with preserved ability to bind with protein a |
EP3094352B1 (en) | 2014-01-16 | 2020-09-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
EP3096797A1 (en) | 2014-01-24 | 2016-11-30 | F. Hoffmann-La Roche AG | Methods of using anti-steap1 antibodies and immunoconjugates |
JP6736467B2 (en) | 2014-02-04 | 2020-08-05 | ジェネンテック, インコーポレイテッド | Smoothing mutant and method of using the same |
SG11201606316XA (en) | 2014-02-08 | 2016-08-30 | Genentech Inc | Methods of treating alzheimer's disease |
WO2015120280A1 (en) | 2014-02-08 | 2015-08-13 | Genentech, Inc. | Methods of treating alzheimer's disease |
TW201902515A (en) | 2014-02-12 | 2019-01-16 | 美商建南德克公司 | Anti-jagged1 antibodies and methods of use |
EP3107574A2 (en) | 2014-02-21 | 2016-12-28 | F. Hoffmann-La Roche AG | Anti-il-13/il-17 bispecific antibodies and uses thereof |
US10183996B2 (en) | 2014-02-28 | 2019-01-22 | Allakos Inc. | Methods and compositions for treating Siglec-8 associated diseases |
NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
KR20160125515A (en) | 2014-03-12 | 2016-10-31 | 노파르티스 아게 | Specific sites for modifying antibodies to make immunoconjugates |
CA3124243A1 (en) | 2014-03-14 | 2015-09-17 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
WO2015139046A1 (en) | 2014-03-14 | 2015-09-17 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US20170107294A1 (en) | 2014-03-21 | 2017-04-20 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
MA39776A (en) | 2014-03-24 | 2017-02-01 | Hoffmann La Roche | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
EP3129767B1 (en) | 2014-03-27 | 2021-09-01 | Academia Sinica | Reactive labelling compounds and uses thereof |
EP3632934A1 (en) | 2014-03-31 | 2020-04-08 | F. Hoffmann-La Roche AG | Anti-ox40 antibodies and methods of use |
MA39817A (en) | 2014-03-31 | 2017-02-08 | Hoffmann La Roche | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
TW201622746A (en) | 2014-04-24 | 2016-07-01 | 諾華公司 | Methods of improving or accelerating physical recovery after surgery for hip fracture |
CA3225091A1 (en) | 2014-05-05 | 2015-11-12 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
CN106414499A (en) | 2014-05-22 | 2017-02-15 | 基因泰克公司 | Anti-GPC3 antibodies and immunoconjugates |
RU2016144405A (en) | 2014-05-23 | 2018-06-26 | Дженентек, Инк. | MiT BIOMARKERS AND WAYS OF THEIR APPLICATION |
TWI679020B (en) | 2014-05-27 | 2019-12-11 | 中央研究院 | Anti-her2 glycoantibodies and uses thereof |
KR20170003720A (en) | 2014-05-27 | 2017-01-09 | 아카데미아 시니카 | Anti-cd20 glycoantibodies and uses thereof |
TWI717319B (en) | 2014-05-27 | 2021-02-01 | 中央研究院 | Fucosidase from bacteroides and methods using the same |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
KR102494193B1 (en) | 2014-05-28 | 2023-01-31 | 아카데미아 시니카 | Anti-tnf-alpha glycoantibodies and uses thereof |
NZ726513A (en) | 2014-05-28 | 2023-07-28 | Memorial Sloan Kettering Cancer Center | Anti-gitr antibodies and methods of use thereof |
RS59643B1 (en) | 2014-06-06 | 2020-01-31 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
EP3155015A1 (en) | 2014-06-11 | 2017-04-19 | F. Hoffmann-La Roche AG | Anti-lgr5 antibodies and uses thereof |
MX2016016310A (en) | 2014-06-11 | 2017-10-20 | A Green Kathy | Use of vista agonists and antagonists to suppress or enhance humoral immunity. |
CN107073121A (en) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | Treatment and the method for prevention cancer drug resistance |
US20170291939A1 (en) | 2014-06-25 | 2017-10-12 | Novartis Ag | Antibodies specific for il-17a fused to hyaluronan binding peptide tags |
AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
WO2015197736A1 (en) | 2014-06-26 | 2015-12-30 | F. Hoffmann-La Roche Ag | Anti-brdu antibodies and methods of use |
TWI726608B (en) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
BR112017000130A2 (en) | 2014-07-11 | 2018-01-09 | Genentech Inc | method for mitigating toxicity associated with notch pathway inhibition and cancer treatment method |
EP3309174B1 (en) | 2014-07-11 | 2022-05-11 | Ventana Medical Systems, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
KR102524920B1 (en) | 2014-07-22 | 2023-04-25 | 아폴로믹스 인코포레이티드 | Anti-pd-1 antibodies |
US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
CN110964108B (en) | 2014-08-05 | 2023-07-07 | 中美冠科生物技术(太仓)有限公司 | anti-PD-L1 antibodies |
EP3194437B1 (en) | 2014-08-07 | 2021-01-20 | Novartis AG | Angiopoietin-like 4 (angptl4) antibodies and methods of use |
PE20170287A1 (en) | 2014-08-07 | 2017-04-05 | Novartis Ag | ANTI-PROTEIN ANTIBODIES SIMILAR TO ANGIOPOYETIN 4 AND METHODS OF USE |
PE20170903A1 (en) | 2014-08-12 | 2017-07-12 | Novartis Ag | DRUG CONJUGATES WITH ANTI-CDH6 ANTIBODIES |
TWI790593B (en) | 2014-08-19 | 2023-01-21 | 美商默沙東有限責任公司 | Anti-tigit antibodies |
JO3663B1 (en) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
AU2015308818B2 (en) | 2014-08-28 | 2021-02-25 | Bioatla Llc | Conditionally active chimeric antigen receptors for modified T-cells |
CN107001404B (en) | 2014-09-08 | 2021-06-29 | 中央研究院 | Activation of human iNKT cells using glycolipids |
SG11201701623UA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Anti-her2 antibodies and immunoconjugates |
AR101844A1 (en) | 2014-09-12 | 2017-01-18 | Genentech Inc | ANTIBODIES AND GENETICALLY MODIFIED CONJUGATES WITH CYSTEINE |
JP6886398B2 (en) | 2014-09-12 | 2021-06-16 | ジェネンテック, インコーポレイテッド | ANTI-CLL-1 antibody and immune complex |
CN113698485A (en) | 2014-09-12 | 2021-11-26 | 基因泰克公司 | anti-B7-H4 antibodies and immunoconjugates |
RU2727663C2 (en) | 2014-09-17 | 2020-07-22 | Дженентек, Инк. | Immunoconjugates, containing antibodies against her2 and pyrrolbenzodiazepines |
EP3689910A3 (en) | 2014-09-23 | 2020-12-02 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
JP6932639B2 (en) | 2014-09-29 | 2021-09-08 | デューク ユニバーシティ | Bispecific molecule with HIV-1 envelope targeting arm |
MA41044A (en) | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
EP3207057A2 (en) | 2014-10-16 | 2017-08-23 | F. Hoffmann-La Roche AG | Anti-alpha-synuclein antibodies and methods of use |
MA41480A (en) | 2014-10-17 | 2017-12-19 | Glenmark Pharmaceuticals Sa | ANTIBODIES BOUND TO CCR6 AND THEIR USES |
EP3215637B1 (en) | 2014-11-03 | 2019-07-03 | F. Hoffmann-La Roche AG | Methods and biomarkers for predicting efficacy and valuation of an ox40 agonist treatment |
AU2015343337A1 (en) | 2014-11-03 | 2017-06-15 | Genentech, Inc. | Assays for detecting T cell immune subsets and methods of use thereof |
AU2015342964B2 (en) | 2014-11-05 | 2021-06-24 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
US10208120B2 (en) | 2014-11-05 | 2019-02-19 | Genentech, Inc. | Anti-FGFR2/3 antibodies and methods using same |
CN108064308B (en) | 2014-11-05 | 2023-06-09 | 豪夫迈·罗氏有限公司 | Method for producing double-stranded protein in bacteria |
RU2714116C2 (en) | 2014-11-06 | 2020-02-11 | Ф. Хоффманн-Ля Рош Аг | VARIANTS OF Fc-DOMAIN WITH MODIFIED FcRn BINDING AND METHODS OF APPLICATION THEREOF |
JP6576456B2 (en) | 2014-11-06 | 2019-09-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Fc region variants with modified FcRn binding properties and protein A binding properties |
EP3215536A1 (en) | 2014-11-06 | 2017-09-13 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
JP6929771B2 (en) | 2014-11-10 | 2021-09-01 | ジェネンテック, インコーポレイテッド | Anti-interleukin-33 antibody and its use |
CN107105632A (en) | 2014-11-10 | 2017-08-29 | 豪夫迈·罗氏有限公司 | Nephrosis animal model and its therapeutic agent |
CA2967188A1 (en) | 2014-11-14 | 2016-05-19 | Novartis Ag | Antibody drug conjugates |
SG10201807625PA (en) | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
JP6993228B2 (en) | 2014-11-19 | 2022-03-03 | ジェネンテック, インコーポレイテッド | Anti-transferrin receptor / anti-BACE1 multispecific antibody and usage |
US10508151B2 (en) | 2014-11-19 | 2019-12-17 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
US10882920B2 (en) | 2014-11-19 | 2021-01-05 | Genentech, Inc. | Antibodies against BACE1 and use thereof for neural disease immunotherapy |
CN107250157B (en) | 2014-11-21 | 2021-06-29 | 百时美施贵宝公司 | Antibodies comprising modified heavy chain constant regions |
CN113773388A (en) | 2014-11-21 | 2021-12-10 | 百时美施贵宝公司 | anti-CD 73 antibodies and uses thereof |
EP3224280A1 (en) | 2014-11-26 | 2017-10-04 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
JP2018505911A (en) | 2014-12-05 | 2018-03-01 | イミュネクスト,インコーポレーテッド | Identification of VSIG8 as a putative VISTA receptor and its use to produce a VISTA / VSIG8 modulator |
DK3227336T3 (en) | 2014-12-05 | 2019-09-16 | Hoffmann La Roche | Anti-CD79b antibodies and methods for use |
US10398774B2 (en) | 2014-12-09 | 2019-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against AXL |
EP3230317A2 (en) | 2014-12-10 | 2017-10-18 | F. Hoffmann-La Roche AG | Blood brain barrier receptor antibodies and methods of use |
UY36449A (en) | 2014-12-19 | 2016-07-29 | Novartis Ag | COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6 |
EP3233921B1 (en) | 2014-12-19 | 2021-09-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
CA2971542A1 (en) | 2014-12-19 | 2016-06-23 | Regenesance B.V. | Antibodies that bind human c6 and uses thereof |
WO2016106286A1 (en) | 2014-12-23 | 2016-06-30 | Biodesy, Inc. | Attachment of proteins to interfaces for use in nonlinear optical detection |
TWI708786B (en) | 2014-12-23 | 2020-11-01 | 美商必治妥美雅史谷比公司 | Antibodies to tigit |
CN107530423B (en) | 2015-01-14 | 2022-04-05 | 布里格姆及妇女医院股份有限公司 | Treatment of cancer with anti-LAP monoclonal antibodies |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
EP3247723A1 (en) | 2015-01-22 | 2017-11-29 | Chugai Seiyaku Kabushiki Kaisha | A combination of two or more anti-c5 antibodies and methods of use |
CN107430127B (en) | 2015-01-24 | 2020-08-28 | 中央研究院 | Cancer markers and methods of use thereof |
JP6779887B2 (en) | 2015-01-24 | 2020-11-04 | アカデミア シニカAcademia Sinica | New glycan conjugate and how to use it |
SG10201907215QA (en) | 2015-02-05 | 2019-09-27 | Chugai Pharmaceutical Co Ltd | Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof |
SG11201706583PA (en) | 2015-02-19 | 2017-09-28 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
US10550173B2 (en) | 2015-02-19 | 2020-02-04 | Compugen, Ltd. | PVRIG polypeptides and methods of treatment |
WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
MA41636A (en) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | METHOD OF TREATMENT OF PRIMITIVE SCLEROSANT CHOLANGITIS |
KR20170131463A (en) | 2015-03-09 | 2017-11-29 | 아르제넥스 비브이비에이 | Methods of Reducing Serum Levels of Fc-Containing Agents Using FcRn Antagonists |
CA2977285A1 (en) | 2015-03-16 | 2016-09-22 | F. Hoffmann-La Roche Ag | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
SG11201707490SA (en) | 2015-04-03 | 2017-10-30 | Eureka Therapeutics Inc | Constructs targeting afp peptide/mhc complexes and uses thereof |
CN107969128A (en) | 2015-04-17 | 2018-04-27 | 高山免疫科学股份有限公司 | Immune modulator with adjustable affinity |
ES2881694T3 (en) | 2015-04-24 | 2021-11-30 | Hoffmann La Roche | Procedures for Identifying Bacteria Comprising Binding Polypeptides |
JP2018520642A (en) | 2015-05-01 | 2018-08-02 | ジェネンテック, インコーポレイテッド | Mask anti-CD3 antibody and method of use thereof |
AU2016256911B2 (en) | 2015-05-07 | 2022-03-31 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
JP6963508B2 (en) | 2015-05-11 | 2021-11-10 | ジェネンテック, インコーポレイテッド | Compositions and Methods for Treating Lupus Nephritis |
CA2983282A1 (en) | 2015-05-12 | 2016-11-17 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
US10526415B2 (en) | 2015-05-22 | 2020-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies fragments inhibiting both the Cath-D catalytic activity and its binding to the LRP1 receptor |
JP2018520658A (en) | 2015-05-29 | 2018-08-02 | ジェネンテック, インコーポレイテッド | Humanized anti-Ebola virus glycoprotein antibodies and uses thereof |
HUE061253T2 (en) | 2015-05-29 | 2023-06-28 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
CA2984003A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
JP2018516933A (en) | 2015-06-02 | 2018-06-28 | ジェネンテック, インコーポレイテッド | Compositions and methods for treating neurological disorders using anti-IL-34 antibodies |
CA2986942A1 (en) | 2015-06-05 | 2016-12-08 | Genentech, Inc. | Anti-tau antibodies and methods of use |
TN2017000417A1 (en) | 2015-06-05 | 2019-01-16 | Novartis Ag | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor |
US20170000885A1 (en) | 2015-06-08 | 2017-01-05 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
KR20180011839A (en) | 2015-06-08 | 2018-02-02 | 제넨테크, 인크. | Treatment of Cancer Using Anti-OX40 Antibody |
CN108064246A (en) | 2015-06-15 | 2018-05-22 | 基因泰克公司 | Antibody and immune conjugate |
JP2018526972A (en) | 2015-06-16 | 2018-09-20 | ジェネンテック, インコーポレイテッド | Anti-CD3 antibody and method of use |
HRP20231134T1 (en) | 2015-06-16 | 2024-01-05 | F. Hoffmann - La Roche Ag | Humanized and affinity matured antibodies to fcrh5 and methods of use |
CN107847568B (en) | 2015-06-16 | 2022-12-20 | 豪夫迈·罗氏有限公司 | anti-CLL-1 antibodies and methods of use |
AU2016280070B2 (en) | 2015-06-17 | 2022-09-15 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes |
AU2016280159A1 (en) | 2015-06-17 | 2017-12-07 | Genentech, Inc. | Anti-HER2 antibodies and methods of use |
AU2016278239B9 (en) | 2015-06-17 | 2022-08-11 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
US9862763B2 (en) | 2015-06-24 | 2018-01-09 | Hoffmann-La Roche Inc. | Humanized anti-tau(pS422) antibodies and methods of use |
CN107922497B (en) | 2015-06-24 | 2022-04-12 | 詹森药业有限公司 | anti-VISTA antibodies and fragments |
HRP20220304T1 (en) | 2015-06-24 | 2022-05-13 | F. Hoffmann - La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
JOP20200312A1 (en) | 2015-06-26 | 2017-06-16 | Novartis Ag | Factor xi antibodies and methods of use |
BR112017027736A2 (en) | 2015-06-29 | 2018-10-09 | Genentech Inc | anti-cd20 type ii antibody for use in organ transplantation |
WO2017001350A1 (en) | 2015-06-29 | 2017-01-05 | Ventana Medical Systems, Inc. | Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin |
EP3971211A1 (en) | 2015-07-13 | 2022-03-23 | Compugen Ltd. | Hide1 compositions and methods |
CN115043944A (en) | 2015-08-03 | 2022-09-13 | 诺华股份有限公司 | Methods of treating FGF 21-associated disorders |
CN108348578B (en) | 2015-08-04 | 2022-08-09 | 阿塞勒隆制药公司 | Methods for treating myeloproliferative disorders |
CN105384825B (en) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
EP3341415B1 (en) | 2015-08-28 | 2021-03-24 | H. Hoffnabb-La Roche Ag | Anti-hypusine antibodies and uses thereof |
WO2017040790A1 (en) | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
TN2018000076A1 (en) | 2015-09-09 | 2019-07-08 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules |
EP3347377B1 (en) | 2015-09-09 | 2021-02-17 | Novartis AG | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
US9862760B2 (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
WO2017049149A1 (en) | 2015-09-17 | 2017-03-23 | Immunogen, Inc. | Therapeutic combinations comprising anti-folr1 immunoconjugates |
IL258088B2 (en) | 2015-09-18 | 2024-02-01 | Chugai Pharmaceutical Co Ltd | Il-8-binding antibodies and uses thereof |
CA2999369C (en) | 2015-09-22 | 2023-11-07 | Spring Bioscience Corporation | Anti-ox40 antibodies and diagnostic uses thereof |
PE20181363A1 (en) | 2015-09-23 | 2018-08-27 | Genentech Inc | OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES |
US11142565B2 (en) | 2015-09-24 | 2021-10-12 | Abvitro Llc | Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope |
AR106188A1 (en) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE |
MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
LT3356411T (en) | 2015-10-02 | 2021-09-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
RU2761115C1 (en) | 2015-10-02 | 2021-12-06 | Ф. Хоффманн-Ля Рош Аг | Bispecific antibodies specific relatively to costimulatory tnf-receptor |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
EP3356406A1 (en) | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
AU2016329251B2 (en) | 2015-10-02 | 2023-02-02 | F. Hoffmann-La Roche Ag | Anti-PD1 antibodies and methods of use |
MY193013A (en) | 2015-10-07 | 2022-09-22 | Hoffmann La Roche | Bispecific antibodies with tetravalency for a costimulatory tnf receptor |
WO2017066714A1 (en) | 2015-10-16 | 2017-04-20 | Compugen Ltd. | Anti-vsig1 antibodies and drug conjugates |
MA43354A (en) | 2015-10-16 | 2018-08-22 | Genentech Inc | CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE |
MA45326A (en) | 2015-10-20 | 2018-08-29 | Genentech Inc | CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
IL295756A (en) | 2015-10-29 | 2022-10-01 | Hoffmann La Roche | Anti-variant fc-region antibodies and methods of use |
JO3555B1 (en) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | Antibody neutralizing human respiratory syncytial virus |
MA44334A (en) | 2015-10-29 | 2018-09-05 | Novartis Ag | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST |
PE20181009A1 (en) | 2015-10-30 | 2018-06-26 | Genentech Inc | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE OF THEM |
TW201730211A (en) | 2015-10-30 | 2017-09-01 | 建南德克公司 | Anti-Factor D antibodies and conjugates |
CN108602884A (en) | 2015-11-08 | 2018-09-28 | 豪夫迈·罗氏有限公司 | The method for screening multi-specificity antibody |
CN108738324B (en) | 2015-11-19 | 2022-06-21 | 百时美施贵宝公司 | Anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and uses thereof |
EP3383903A1 (en) | 2015-11-30 | 2018-10-10 | Bristol-Myers Squibb Company | Anti human ip-10 antibodies and their uses |
CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
MX2018006778A (en) | 2015-12-04 | 2018-08-01 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation. |
BR112018012352A2 (en) | 2015-12-16 | 2018-12-11 | Merck Sharp & Dohme Corp. | anti-lag3 antibodies and antigen binding fragments |
CN109069623A (en) | 2015-12-18 | 2018-12-21 | 诺华股份有限公司 | Target the antibody and its application method of CD32b |
CA3048204A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response |
PL3400246T3 (en) | 2016-01-08 | 2021-03-08 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
CA3011739A1 (en) | 2016-01-20 | 2017-07-27 | Genentech, Inc. | High dose treatments for alzheimer's disease |
WO2017136558A1 (en) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened and methods of using the same |
TWI756204B (en) | 2016-02-12 | 2022-03-01 | 比利時商楊森製藥公司 | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
CN114395624A (en) | 2016-02-29 | 2022-04-26 | 基因泰克公司 | Methods for treatment and diagnosis of cancer |
AU2017228470A1 (en) | 2016-03-04 | 2018-08-30 | Bristol-Myers Squibb Company | Combination therapy with anti-CD73 antibodies |
CA3016170A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
CN117298268A (en) | 2016-03-14 | 2023-12-29 | 千禧制药公司 | Methods of treating or preventing graft versus host disease |
EP3430052A2 (en) | 2016-03-14 | 2019-01-23 | Millennium Pharmaceuticals, Inc. | Method of preventing graft versus host disease |
MX2018010546A (en) | 2016-03-15 | 2019-02-20 | Chugai Pharmaceutical Co Ltd | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies. |
CN108884142A (en) | 2016-03-16 | 2018-11-23 | 梅里麦克制药股份有限公司 | Engineering TRAIL use for cancer treatment |
EP3433272A1 (en) | 2016-03-22 | 2019-01-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Humanized anti-claudin-1 antibodies and uses thereof |
WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
WO2017165778A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
JP6943872B2 (en) | 2016-03-25 | 2021-10-06 | ジェネンテック, インコーポレイテッド | Multiple whole antibody and antibody complex drug quantification assay |
EP3443004A1 (en) | 2016-04-14 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Anti-rspo3 antibodies and methods of use |
WO2017181143A1 (en) | 2016-04-15 | 2017-10-19 | Generon (Shanghai) Corporation, Ltd. | Use of il-22 in treating necrotizing enterocolitis |
CN109154613A (en) | 2016-04-15 | 2019-01-04 | 豪夫迈·罗氏有限公司 | For monitoring and the method for the treatment of cancer |
CN109069633A (en) | 2016-04-15 | 2018-12-21 | 宏观基因有限公司 | Novel B7-H3- binding molecule, its antibody drug conjugate and its application method |
SG11201808994YA (en) | 2016-04-15 | 2018-11-29 | Bioatla Llc | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
EP3443120A2 (en) | 2016-04-15 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Methods for monitoring and treating cancer |
SG11201808783XA (en) | 2016-04-15 | 2018-11-29 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
CN110088126A (en) | 2016-04-15 | 2019-08-02 | 高山免疫科学股份有限公司 | ICOS ligand variant immune modulator and application thereof |
SG11201808633RA (en) | 2016-04-15 | 2018-10-30 | Immunext Inc | Anti-human vista antibodies and use thereof |
CN109071647B (en) | 2016-04-27 | 2022-11-22 | 诺华股份有限公司 | Anti-growth differentiation factor 15 antibody and application thereof |
UA123323C2 (en) | 2016-05-02 | 2021-03-17 | Ф. Хоффманн-Ля Рош Аг | The contorsbody - a single chain target binder |
WO2017196663A1 (en) | 2016-05-09 | 2017-11-16 | Bristol-Myers Squibb Company | Tl1a antibodies and uses thereof |
EP3455252B1 (en) | 2016-05-11 | 2022-02-23 | F. Hoffmann-La Roche AG | Modified anti-tenascin antibodies and methods of use |
IL308504A (en) | 2016-05-13 | 2024-01-01 | Bioatla Llc | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
PL3458101T3 (en) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Protac antibody conjugates and methods of use |
TW201802121A (en) | 2016-05-25 | 2018-01-16 | 諾華公司 | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
KR102366813B1 (en) | 2016-05-27 | 2022-02-24 | 아게누스 인코포레이티드 | Anti-TIM-3 Antibodies and Methods of Using Same |
US20170370906A1 (en) | 2016-05-27 | 2017-12-28 | Genentech, Inc. | Bioanalytical analysis of site-specific antibody drug conjugates |
WO2017214024A1 (en) | 2016-06-06 | 2017-12-14 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
WO2017218434A1 (en) | 2016-06-12 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | Method of treating inflammatory bowel disease |
CN110381988A (en) | 2016-06-15 | 2019-10-25 | 诺华股份有限公司 | Use the method for the inhibitor for treating disease of Bone Morphogenetic Protein 6 (BMP6) |
CN109563160B (en) | 2016-06-24 | 2023-02-28 | 豪夫迈·罗氏有限公司 | Anti-polyubiquitin multispecific antibodies |
WO2018007314A1 (en) | 2016-07-04 | 2018-01-11 | F. Hoffmann-La Roche Ag | Novel antibody format |
AU2017293423B2 (en) | 2016-07-05 | 2023-05-25 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
PE20190418A1 (en) | 2016-07-14 | 2019-03-19 | Bristol Myers Squibb Co | ANTIBODIES AGAINST PROTEIN 3 CONTAINING THE MUCIN AND IMMUNOGLOBULIN T-LYMPHOCYTE DOMAIN (TIM3) AND THEIR USES |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
WO2018022479A1 (en) | 2016-07-25 | 2018-02-01 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
CA3032120A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
AU2017303205A1 (en) | 2016-07-29 | 2019-01-17 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity |
NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
MX2019001471A (en) | 2016-08-05 | 2019-10-30 | Allakos Inc | Anti-siglec-7 antibodies for the treatment of cancer. |
CN116271014A (en) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | Compositions for preventing or treating IL-8 related diseases |
WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
CN109689111B (en) | 2016-08-11 | 2024-04-05 | 基因泰克公司 | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
WO2018033135A1 (en) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
JP7213549B2 (en) | 2016-08-22 | 2023-01-27 | シーエイチオー ファーマ インコーポレイテッド | Antibodies, Binding Fragments, and Methods of Use |
US10981976B2 (en) | 2016-08-31 | 2021-04-20 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
CN109689682B (en) | 2016-09-19 | 2022-11-29 | 豪夫迈·罗氏有限公司 | Complement factor-based affinity chromatography |
LT3528838T (en) | 2016-09-23 | 2023-10-10 | F. Hoffmann-La Roche Ag | Uses of il-13 antagonists for treating atopic dermatitis |
JOP20190055A1 (en) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | Anti-cd27 antibodies |
WO2018065501A1 (en) | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Methods for preparing antibody drug conjugates |
MX2019003934A (en) | 2016-10-06 | 2019-07-10 | Genentech Inc | Therapeutic and diagnostic methods for cancer. |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
IL265800B2 (en) | 2016-10-11 | 2023-10-01 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
EP3532091A2 (en) | 2016-10-29 | 2019-09-04 | H. Hoffnabb-La Roche Ag | Anti-mic antibidies and methods of use |
EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
CN109996809A (en) | 2016-11-14 | 2019-07-09 | 诺华股份有限公司 | Composition relevant to fusogenic protein MINION, method and therapeutical uses |
MX2019005438A (en) | 2016-11-15 | 2019-08-16 | Genentech Inc | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies. |
TW201829463A (en) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | Anti-hla-g antibodies and use thereof |
JOP20190100A1 (en) | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | Anti-gitr antigen-binding proteins and methods of use thereof |
NZ750948A (en) | 2016-11-21 | 2020-06-26 | Cureab Gmbh | Anti-gp73 antibodies and immunoconjugates |
AU2017363309A1 (en) | 2016-11-23 | 2019-07-11 | Bioverativ Therapeutics Inc. | Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X |
KR102603681B1 (en) | 2016-12-07 | 2023-11-17 | 아게누스 인코포레이티드 | Antibodies and methods of using them |
AU2017373889A1 (en) | 2016-12-07 | 2019-06-06 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
MA50949B1 (en) | 2016-12-07 | 2023-12-29 | Memorial Sloan Kettering Cancer Center | ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF |
CN110248959B (en) | 2016-12-07 | 2023-06-30 | 基因泰克公司 | anti-TAU antibodies and methods of use |
CN110366562A (en) | 2016-12-12 | 2019-10-22 | 豪夫迈·罗氏有限公司 | Use the method for anti-PD-L1 antibody and anti-androgen therapy cancer |
CN111868086A (en) | 2016-12-19 | 2020-10-30 | 马赛克生物医学一人有限责任公司 | anti-LIF antibodies and uses thereof |
US10583191B2 (en) | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
JP7247091B2 (en) | 2016-12-20 | 2023-03-28 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Combination therapy with anti-CD20/anti-CD3 bispecific antibody and 4-1BB (CD137) agonist |
IL308980A (en) | 2016-12-23 | 2024-01-01 | Novartis Ag | Factor xi antibodies and methods of use |
JOP20190134A1 (en) | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | Anti-neuropilin antigen-binding proteins and methods of use thereof |
TW201829469A (en) | 2017-01-03 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
TW201833140A (en) | 2017-01-09 | 2018-09-16 | 美商莫瑞麥克製藥公司 | Anti-fgfr antibodies and methods of use |
TW201831517A (en) | 2017-01-12 | 2018-09-01 | 美商優瑞科生物技術公司 | Constructs targeting histone h3 peptide/mhc complexes and uses thereof |
US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
EP4223774A3 (en) | 2017-01-31 | 2023-09-27 | Chugai Seiyaku Kabushiki Kaisha | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
JOP20190187A1 (en) | 2017-02-03 | 2019-08-01 | Novartis Ag | Anti-ccr7 antibody drug conjugates |
KR102572663B1 (en) | 2017-02-08 | 2023-09-01 | 노파르티스 아게 | FGF21 Mimetic Antibodies and Uses Thereof |
UA126574C2 (en) | 2017-02-10 | 2022-11-02 | Дженентек, Інк. | Anti-tryptase antibodies, compositions thereof, and uses thereof |
SG11201906947SA (en) | 2017-02-17 | 2019-08-27 | Bristol Myers Squibb Co | Antibodies to alpha-synuclein and uses thereof |
KR102602199B1 (en) | 2017-02-27 | 2023-11-15 | 리제너론 파아마슈티컬스, 인크. | Humanized Models of Kidney and Liver Disorders |
EP3589754B1 (en) | 2017-03-01 | 2023-06-28 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for cancer |
US11274160B2 (en) | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
EP3596115A1 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
HUE064136T2 (en) | 2017-03-16 | 2024-02-28 | Alpine Immune Sciences Inc | Pd-l1 variant immunomodulatory proteins and uses thereof |
BR112019018747A2 (en) | 2017-03-16 | 2020-05-05 | Alpine Immune Sciences Inc | variant immunomodulatory proteins of cd80 and uses thereof |
JP7227151B2 (en) | 2017-03-22 | 2023-02-21 | ジェネンテック, インコーポレイテッド | Antibody Compositions Optimized for Treatment of Eye Disorders |
WO2018175460A1 (en) | 2017-03-24 | 2018-09-27 | Novartis Ag | Methods for preventing and treating heart disease |
SG10201911225WA (en) | 2017-03-28 | 2020-01-30 | Genentech Inc | Methods of treating neurodegenerative diseases |
WO2018178055A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
WO2018178076A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
JOP20190203A1 (en) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | Anti-tigit antigen-binding proteins and methods of use thereof |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
BR112019017753A2 (en) | 2017-04-04 | 2020-04-07 | Hoffmann La Roche | bispecific molecule, polynucleotide, vector, cell, methods for the production of a molecule and for the treatment of an individual, composition and use of the bispecific molecule |
SI3606954T1 (en) | 2017-04-05 | 2022-10-28 | F. Hoffmann - La Roche Ag | Anti-lag3 antibodies |
KR102408873B1 (en) | 2017-04-05 | 2022-06-15 | 에프. 호프만-라 로슈 아게 | Bispecific antibodies specifically binding to pd1 and lag3 |
TWI796329B (en) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | Anti-ilt4 antibodies and antigen-binding fragments |
SG11201908813QA (en) | 2017-04-13 | 2019-10-30 | Aduro Biotech Holdings Europe B V | Anti-sirp alpha antibodies |
TW201841942A (en) | 2017-04-13 | 2018-12-01 | 美商艾吉納斯公司 | Anti-CD137 antibodies and methods of use thereof |
MX2019012192A (en) | 2017-04-14 | 2020-01-21 | Genentech Inc | Diagnostic and therapeutic methods for cancer. |
EP3624820A1 (en) | 2017-04-21 | 2020-03-25 | H. Hoffnabb-La Roche Ag | Use of klk5 antagonists for treatment of a disease |
AU2018258049A1 (en) | 2017-04-26 | 2019-12-12 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
US20220135670A1 (en) | 2017-04-27 | 2022-05-05 | Tesaro, Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
KR20190141148A (en) | 2017-04-28 | 2019-12-23 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | How to treat pediatric disorders |
AR111651A1 (en) | 2017-04-28 | 2019-08-07 | Novartis Ag | CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES |
MA50957A (en) | 2017-05-01 | 2020-10-14 | Agenus Inc | ANTI-TIGIT ANTIBODIES AND THEIR METHODS OF USE |
ES2948647T3 (en) | 2017-05-04 | 2023-09-15 | Acceleron Pharma Inc | TGF-beta type II receptor fusion proteins and uses thereof |
US11203638B2 (en) | 2017-05-05 | 2021-12-21 | Allakos Inc. | Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis |
CN111094335B (en) | 2017-05-15 | 2022-08-23 | 罗切斯特大学 | Broadly neutralizing anti-influenza monoclonal antibodies and uses thereof |
WO2018215938A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
CN110662762A (en) | 2017-05-24 | 2020-01-07 | 诺华股份有限公司 | Antibody cytokine transplantation proteins and methods for treating cancer |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
JOP20190271A1 (en) | 2017-05-24 | 2019-11-21 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use for immune related disorders |
CN116333129A (en) | 2017-05-25 | 2023-06-27 | 百时美施贵宝公司 | Antibodies comprising modified heavy chain constant regions |
BR112019025035A2 (en) | 2017-06-01 | 2020-06-30 | Compugen Ltd. | method to treat cancer |
UY37758A (en) | 2017-06-12 | 2019-01-31 | Novartis Ag | METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
WO2018229706A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Combination therapy for the treatment of cancer |
US20190062428A1 (en) | 2017-06-19 | 2019-02-28 | Surface Oncology, Inc. | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof |
KR20200019122A (en) | 2017-06-20 | 2020-02-21 | 암젠 인크 | Methods of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptors (GIPR) in combination with GLP-1 agonists |
EP3641752A4 (en) | 2017-06-22 | 2021-03-17 | Moonshot Pharma LLC | Methods for treating cancer with compositions comprising amlexanox and immune modulators |
TWI804499B (en) | 2017-06-23 | 2023-06-11 | 美商維洛斯生物公司 | Ror1 antibody immunoconjugates |
AU2018290532A1 (en) | 2017-06-26 | 2019-11-21 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
JP2020525421A (en) | 2017-06-28 | 2020-08-27 | ノバルティス アーゲー | Methods for preventing and treating urinary incontinence |
SG11201913137VA (en) | 2017-07-11 | 2020-01-30 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
KR20200093518A (en) | 2017-07-21 | 2020-08-05 | 제넨테크, 인크. | Methods of treatment and diagnosis for cancer |
US10961318B2 (en) | 2017-07-26 | 2021-03-30 | Forty Seven, Inc. | Anti-SIRP-α antibodies and related methods |
BR112020001657A2 (en) | 2017-07-27 | 2020-07-21 | Daiichi Sankyo Company, Limited | ANTIBODY AGAINST HUMAN CD147, ANTIBODY ANTIGEN BINDING FRAGMENT, PHARMACEUTICAL COMPOSITION, ANTIBODY OR ANTIGEN BINDING FRAGMENT, POLYNUCLEOTIDE ANTIBODY, EXPRESSION VECTOR, HOSEPHORUS CELL , TO PROGNOSTIC RESPONSIVITY TO CANCER TREATMENT AND TO SELECT SUBJECTS FOR CANCER TREATMENT, KIT TO DETERMINE RESPONSIVENESS TO CANCER TREATMENT, ANTIBODY AND ANTIBODY COMPOUND BODY, |
EP3665197A2 (en) | 2017-08-11 | 2020-06-17 | H. Hoffnabb-La Roche Ag | Anti-cd8 antibodies and uses thereof |
EP3684811A2 (en) | 2017-08-17 | 2020-07-29 | Massachusetts Institute of Technology | Multiple specificity binders of cxc chemokines and uses thereof |
BR112020003533A2 (en) | 2017-08-25 | 2020-11-17 | Five Prime Therapeutics, Inc. | b7-h4 antibodies and methods of using them |
EP3684413A1 (en) | 2017-09-20 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
BR112020004126A2 (en) | 2017-09-29 | 2020-09-08 | Daiichi Sankyo Company, Limited | antibody-derived pyrrolbenzodiazepine conjugate |
BR112020005834A2 (en) | 2017-09-29 | 2020-09-24 | Chugai Seiyaku Kabushiki Kaisha | multispecific antigen binding molecule having blood clotting factor viii cofactor function (fviii) replacement activity, and pharmaceutical formulation containing said molecule as an active ingredient |
WO2019074983A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
CA3078974A1 (en) | 2017-10-12 | 2019-04-18 | Immunowake Inc. | Vegfr-antibody light chain fusion protein |
WO2019079520A2 (en) | 2017-10-18 | 2019-04-25 | Alpine Immune Sciences, Inc. | Variant icos ligand immunomodulatory proteins and related compositions and methods |
WO2019077092A1 (en) | 2017-10-20 | 2019-04-25 | F. Hoffmann-La Roche Ag | Method for generating multispecific antibodies from monospecific antibodies |
EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
CN111372947A (en) | 2017-10-30 | 2020-07-03 | 豪夫迈·罗氏有限公司 | Method for generating multispecific antibodies from monospecific antibodies in vivo |
WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
MX2020004567A (en) | 2017-11-06 | 2020-08-13 | Genentech Inc | Diagnostic and therapeutic methods for cancer. |
EP3713965A1 (en) | 2017-11-22 | 2020-09-30 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
US11433132B2 (en) | 2017-12-01 | 2022-09-06 | Novartis Ag | Polyomavirus neutralizing antibodies |
AU2018380979B2 (en) | 2017-12-08 | 2023-07-20 | Argenx Bvba | Use of FcRn antagonists for treatment of generalized myasthenia gravis |
US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
US20210087267A1 (en) | 2017-12-20 | 2021-03-25 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
US20190211098A1 (en) | 2017-12-22 | 2019-07-11 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
WO2019129221A1 (en) | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against tigit |
KR20200104886A (en) | 2017-12-28 | 2020-09-04 | 난징 레전드 바이오테크 씨오., 엘티디. | Antibodies and variants against PD-L1 |
WO2019129679A1 (en) | 2017-12-29 | 2019-07-04 | F. Hoffmann-La Roche Ag | Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody |
EP3735417A1 (en) | 2018-01-03 | 2020-11-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
CN111886247A (en) | 2018-01-05 | 2020-11-03 | Ac免疫有限公司 | Misfolded TDP-43 binding molecules |
CN111886255A (en) | 2018-01-12 | 2020-11-03 | 百时美施贵宝公司 | anti-TIM 3 antibodies and uses thereof |
SG11202004233UA (en) | 2018-01-15 | 2020-06-29 | Nanjing Legend Biotech Co Ltd | Single-domain antibodies and variants thereof against pd-1 |
US20200339686A1 (en) | 2018-01-16 | 2020-10-29 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
JP7349995B2 (en) | 2018-01-26 | 2023-09-25 | ジェネンテック, インコーポレイテッド | IL-22 Fc fusion protein and method of use |
JP7345479B2 (en) | 2018-01-26 | 2023-09-15 | ジェネンテック, インコーポレイテッド | Composition and method of use |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
AR115360A1 (en) | 2018-02-08 | 2021-01-13 | Genentech Inc | ANTIGEN BINDING MOLECULES AND METHODS OF USE |
MA51741A (en) | 2018-02-09 | 2021-05-19 | Hoffmann La Roche | THERAPEUTIC AND DIAGNOSIS PROCEDURES FOR INFLAMMATORY DISEASES MEDIATED BY MASTOCYTES |
JP7350756B2 (en) | 2018-02-14 | 2023-09-26 | アバ セラピューティクス アーゲー | Anti-human PD-L2 antibody |
EP3755364A1 (en) | 2018-02-21 | 2020-12-30 | F. Hoffmann-La Roche AG | Dosing for treatment with il-22 fc fusion proteins |
CA3092108A1 (en) | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
AU2019228600A1 (en) | 2018-03-02 | 2020-09-24 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
NL2020520B1 (en) | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
BR112020017451A2 (en) | 2018-03-05 | 2020-12-22 | Saitama Medical University | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF HETEROTOPIC OSSIFICATION |
AU2019236372A1 (en) | 2018-03-13 | 2020-07-30 | F. Hoffmann-La Roche Ag | Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies |
NZ782442A (en) | 2018-03-14 | 2022-01-28 | Surface Oncology Inc | Antibodies that bind cd39 and uses thereof |
US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
CN112119090B (en) | 2018-03-15 | 2023-01-13 | 中外制药株式会社 | Anti-dengue virus antibodies cross-reactive to Zika virus and methods of use |
US11661452B2 (en) | 2018-03-20 | 2023-05-30 | WuXi Biologics Ireland Limited | Anti-lag-3 antibody polypeptide |
TW201945393A (en) | 2018-03-21 | 2019-12-01 | 美商戊瑞治療有限公司 | Antibodies binding to VISTA at acidic pH |
US11332524B2 (en) | 2018-03-22 | 2022-05-17 | Surface Oncology, Inc. | Anti-IL-27 antibodies and uses thereof |
TW202003565A (en) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | Antibodies against MICA and/or MICB and uses thereof |
JP2021519073A (en) | 2018-03-29 | 2021-08-10 | ジェネンテック, インコーポレイテッド | Regulation of lactogenic activity in mammalian cells |
JOP20200240A1 (en) | 2018-04-02 | 2020-09-27 | Bristol Myers Squibb Co | Anti-trem-1 antibodies and uses thereof reference to sequence listing submitted electronically via efs-web |
TW202011029A (en) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | Methods for detecting and quantifying FGF21 |
EP3552631A1 (en) | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
WO2019200357A1 (en) | 2018-04-12 | 2019-10-17 | Surface Oncology, Inc. | Biomarker for cd47 targeting therapeutics and uses therefor |
US20210130453A1 (en) | 2018-04-12 | 2021-05-06 | Medimmune Limited | Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer |
AR115052A1 (en) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM |
AR114789A1 (en) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | ANTI-HLA-G ANTIBODIES AND THE USE OF THEM |
JP7402541B2 (en) | 2018-05-03 | 2023-12-21 | ユニバーシティ オブ ロチェスター | Anti-influenza neuraminidase monoclonal antibody and its use |
CN110464842B (en) | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | Formulations comprising anti-PCSK 9 antibodies and uses thereof |
AU2019271148B2 (en) | 2018-05-14 | 2023-07-06 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
KR20210008514A (en) | 2018-05-14 | 2021-01-22 | 메디뮨 리미티드 | Antibodies to LIF and dosage forms thereof |
BR112020023118A2 (en) | 2018-05-14 | 2021-04-13 | Werewolf Therapeutics, Inc. | ACTIVE ACTIVABLE INTERLEUKIN POLYPEPTIDS 12 AND METHODS OF USE OF THESE |
AR126019A1 (en) | 2018-05-30 | 2023-09-06 | Novartis Ag | ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES |
WO2019229699A1 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Hepatitis b antibodies |
EP3802611A2 (en) | 2018-06-01 | 2021-04-14 | Novartis AG | Binding molecules against bcma and uses thereof |
JP7372237B2 (en) | 2018-06-04 | 2023-10-31 | 中外製薬株式会社 | Antigen-binding molecules with altered half-lives in the cytoplasm |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
JP7379390B2 (en) | 2018-06-18 | 2023-11-14 | メドイミューン・リミテッド | Combination of LIF inhibitor and platinum-based antineoplastic agent for use in cancer treatment |
BR112020026384A2 (en) | 2018-06-23 | 2021-03-30 | Genentech, Inc. | METHODS FOR TREATING AN INDIVIDUAL WITH LUNG CANCER AND FOR TREATING AN INDIVIDUAL WITH SMALL CELL LUNG CANCER, KITS, ANTIBODY ANTI-PD-L1 AND COMPOSITION |
CN112424228A (en) | 2018-07-04 | 2021-02-26 | 豪夫迈·罗氏有限公司 | Novel bispecific agonistic 4-1BB antigen-binding molecules |
SG11202100096XA (en) | 2018-07-09 | 2021-02-25 | Five Prime Therapeutics Inc | Antibodies binding to ilt4 |
US20210155707A1 (en) | 2018-07-10 | 2021-05-27 | National University Corporation Kobe University | ANTI-SIRPalpha ANTIBODY |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
CA3104536A1 (en) | 2018-07-11 | 2020-01-16 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
US20200171146A1 (en) | 2018-07-18 | 2020-06-04 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
EP3823673A4 (en) | 2018-07-20 | 2022-05-11 | Surface Oncology, Inc. | Anti-cd112r compositions and methods |
SG11202101038SA (en) | 2018-08-01 | 2021-02-25 | Imcheck Therapeutics Sas | Anti-btn3a antibodies and their use in treating cancer or infectious disorders |
KR20210037743A (en) | 2018-08-01 | 2021-04-06 | 추가이 세이야쿠 가부시키가이샤 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
US20220195045A1 (en) | 2018-08-03 | 2022-06-23 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing two antigen-binding domains that are linked to each other |
US20210388089A1 (en) | 2018-08-09 | 2021-12-16 | Compass Therapeutics Llc | Antigen binding agents that bind cd277 and uses thereof |
US20210309746A1 (en) | 2018-08-09 | 2021-10-07 | Compass Therapeutics Llc | Antibodies that bind cd277 and uses thereof |
MA50586A (en) | 2018-08-09 | 2020-09-16 | Regeneron Pharma | METHODS FOR EVALUATING THE BINDING AFFINITY OF AN ANTIBODY VARIANT TO THE NEONATAL FC RECEPTOR |
WO2020033925A2 (en) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Antibodies that bind cd277 and uses thereof |
BR112021002037A2 (en) | 2018-08-10 | 2021-05-04 | Chugai Seiyaku Kabushiki Kaisha | anti-cd137 antigen binding molecule and its use |
TW202021618A (en) | 2018-08-17 | 2020-06-16 | 美商23與我有限公司 | Anti-il1rap antibodies and methods of use thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
KR20230122685A (en) | 2018-09-06 | 2023-08-22 | 다이이찌 산쿄 가부시키가이샤 | Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof |
WO2020053742A2 (en) | 2018-09-10 | 2020-03-19 | Novartis Ag | Anti-hla-hbv peptide antibodies |
TW202019480A (en) | 2018-09-13 | 2020-06-01 | 美國德州系統大學評議委員會 | Novel lilrb4 antibodies and uses thereof |
US20220177587A1 (en) | 2018-09-19 | 2022-06-09 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
EP3853611A1 (en) | 2018-09-19 | 2021-07-28 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for bladder cancer |
EP3857230B1 (en) | 2018-09-21 | 2023-06-07 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
JP2022502088A (en) | 2018-09-27 | 2022-01-11 | エクシリオ デベロップメント, インコーポレイテッド | Masked cytokine polypeptide |
CN112654641A (en) | 2018-10-01 | 2021-04-13 | 豪夫迈·罗氏有限公司 | Bispecific antigen binding molecules with trivalent binding to CD40 |
US11242396B2 (en) | 2018-10-01 | 2022-02-08 | Hoffmann-La Roche Inc. | Bispecific antigen binding molecules comprising anti-FAP clone 212 |
WO2020076969A2 (en) | 2018-10-10 | 2020-04-16 | Tilos Therapeutics, Inc. | Anti-lap antibody variants and uses thereof |
UY38407A (en) | 2018-10-15 | 2020-05-29 | Novartis Ag | TREM2 STABILIZING ANTIBODIES |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
KR20210079311A (en) | 2018-10-18 | 2021-06-29 | 제넨테크, 인크. | Diagnosis and treatment methods for sarcoma renal cancer |
EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
TW202031899A (en) | 2018-11-05 | 2020-09-01 | 美商建南德克公司 | Methods of producing two chain proteins in prokaryotic host cells |
AU2019375422A1 (en) | 2018-11-07 | 2021-05-27 | Daiichi Sankyo Company, Limited | Method of improving blood kinetics of peptide |
US20210403597A1 (en) | 2018-11-16 | 2021-12-30 | Memorial Sloan Kettering Cancer Center | Antibodies to mucin-16 and methods of use thereof |
KR20210096559A (en) | 2018-11-27 | 2021-08-05 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | Anti-IL-23p19 antibodies and uses thereof |
WO2020112781A1 (en) | 2018-11-28 | 2020-06-04 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
CN113727998A (en) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | CD86 variant immunomodulatory proteins and uses thereof |
JP2022511502A (en) | 2018-12-05 | 2022-01-31 | ジェネンテック, インコーポレイテッド | Diagnostic Methods and Diagnostic Compositions for Cancer Immunotherapy |
KR20210100668A (en) | 2018-12-06 | 2021-08-17 | 제넨테크, 인크. | Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugate, an alkylating agent and an anti-CD20 antibody |
US20220098310A1 (en) | 2018-12-06 | 2022-03-31 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
CA3120059A1 (en) | 2018-12-14 | 2020-06-18 | Boehringer Ingelheim Io Canada Inc. | Anti-periostin antibodies and uses thereof |
WO2020128863A1 (en) | 2018-12-19 | 2020-06-25 | Novartis Ag | Anti-tnf-alpha antibodies |
AR117453A1 (en) | 2018-12-20 | 2021-08-04 | Genentech Inc | CF OF MODIFIED ANTIBODIES AND METHODS TO USE THEM |
AR117327A1 (en) | 2018-12-20 | 2021-07-28 | 23Andme Inc | ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THEM |
BR112021011900A2 (en) | 2018-12-21 | 2021-09-08 | Novartis Ag | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF |
MX2021007421A (en) | 2018-12-21 | 2021-08-05 | Hoffmann La Roche | Antibody that binds to vegf and il-1beta and methods of use. |
JP2022514950A (en) | 2018-12-21 | 2022-02-16 | 23アンドミー・インコーポレイテッド | Anti-IL-36 antibody and how to use it |
CA3121804A1 (en) | 2018-12-21 | 2020-06-25 | Genentech, Inc. | Methods of producing polypeptides using a cell line resistant to apoptosis |
EP3902832A2 (en) | 2018-12-26 | 2021-11-03 | Xilio Development, Inc. | Anti-ctla4 antibodies and methods of use thereof |
CN113272327A (en) | 2018-12-30 | 2021-08-17 | 豪夫迈·罗氏有限公司 | Anti-rabbit CD19 antibodies and methods of use thereof |
TW202043272A (en) | 2019-01-14 | 2020-12-01 | 美商建南德克公司 | Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine |
WO2020148207A1 (en) | 2019-01-14 | 2020-07-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies binding to hla-a2 |
MX2021008453A (en) | 2019-01-16 | 2021-08-19 | Compass Therapeutics Llc | Formulations of antibodies that bind human cd137 and uses thereof. |
EP3914622A1 (en) | 2019-01-22 | 2021-12-01 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
KR20210118881A (en) | 2019-01-22 | 2021-10-01 | 제넨테크, 인크. | Immunoglobulin A Antibodies and Methods of Production and Use |
CA3124515A1 (en) | 2019-01-23 | 2020-07-30 | Genentech, Inc. | Methods of producing multimeric proteins in eukaryotic host cells |
CN113329770A (en) | 2019-01-24 | 2021-08-31 | 中外制药株式会社 | Novel cancer antigen and antibody against said antigen |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
CA3130695A1 (en) | 2019-02-27 | 2020-09-03 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies |
WO2020185535A1 (en) | 2019-03-08 | 2020-09-17 | Genentech, Inc. | Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles |
JP2022524074A (en) | 2019-03-14 | 2022-04-27 | ジェネンテック, インコーポレイテッド | Treatment of cancer with HER2xCD3 bispecific antibodies in combination with anti-HER2 MAB |
EP3950061A4 (en) | 2019-03-25 | 2022-11-16 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
CN113631191A (en) | 2019-03-27 | 2021-11-09 | 第一三共株式会社 | Combination of antibody-pyrrolobenzodiazepine derivative conjugates with PARP inhibitors |
KR20220005471A (en) | 2019-04-08 | 2022-01-13 | 바이오젠 엠에이 인코포레이티드 | Anti-integrin antibodies and uses thereof |
GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
CN114302736A (en) | 2019-04-17 | 2022-04-08 | 高山免疫科学股份有限公司 | Methods and uses of variant ICOS ligand (ICOSL) fusion proteins |
SG11202111345PA (en) | 2019-04-19 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Chimeric receptor that recognizes engineered site in antibody |
MX2021012692A (en) | 2019-04-19 | 2021-11-12 | Genentech Inc | Anti-mertk antibodies and their methods of use. |
CN114269376A (en) | 2019-05-03 | 2022-04-01 | 豪夫迈·罗氏有限公司 | Methods of treating cancer with anti-PD-L1 antibodies |
CA3138045C (en) | 2019-05-14 | 2024-02-20 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma |
EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
WO2020236841A2 (en) | 2019-05-20 | 2020-11-26 | Novartis Ag | Antibody drug conjugates having linkers comprising hydrophilic groups |
JOP20210289A1 (en) | 2019-05-20 | 2023-01-30 | Servier Lab | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
CR20210576A (en) | 2019-05-21 | 2021-12-15 | Novartis Ag | Cd19 binding molecules and uses thereof |
JP2022537887A (en) | 2019-05-21 | 2022-08-31 | ノバルティス アーゲー | Trispecific binding molecules for BCMA and uses thereof |
AU2020278907A1 (en) | 2019-05-23 | 2022-01-20 | Ac Immune Sa | Anti-TDP-43 binding molecules and uses thereof |
CA3138072A1 (en) | 2019-06-07 | 2020-12-10 | Argenx Bvba | Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration |
EP3983437A1 (en) | 2019-06-12 | 2022-04-20 | Novartis AG | Natriuretic peptide receptor 1 antibodies and methods of use |
PE20220231A1 (en) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | FLT3L-FC FUSION PROTEINS AND METHODS OF USE |
JP7354306B2 (en) | 2019-06-27 | 2023-10-02 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Novel ICOS antibodies and tumor-targeting antigen-binding molecules containing them |
JPWO2021010326A1 (en) | 2019-07-12 | 2021-01-21 | ||
AR119382A1 (en) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | PRE-TARGETING ANTIBODIES AND METHODS OF USE |
CN114174536A (en) | 2019-07-15 | 2022-03-11 | 百时美施贵宝公司 | anti-TREM-1 antibodies and uses thereof |
CN114144435A (en) | 2019-07-15 | 2022-03-04 | 百时美施贵宝公司 | Antibodies against human TREM-1 and uses thereof |
CN114258401A (en) | 2019-07-16 | 2022-03-29 | Inserm(法国国家健康医学研究院) | Antibodies specific for CD38 and uses thereof |
BR112021005478A2 (en) | 2019-07-24 | 2021-06-15 | H. Lundbeck A/S | anti-mglur5 antibodies and their use |
US20220267453A1 (en) | 2019-07-26 | 2022-08-25 | Saitama Medical University | Antibody recognizing extracellular region of alk2/acvr1 |
AU2020323926A1 (en) | 2019-07-29 | 2022-03-10 | Compugen Ltd. | Anti-PVRIG antibodies formulations and uses thereof |
CA3144923A1 (en) | 2019-07-31 | 2021-02-04 | Alexandre Antoine Bernard SOSTELLY | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
CN114466660A (en) | 2019-07-31 | 2022-05-10 | 豪夫迈·罗氏有限公司 | Dosage and administration regimen for treating or preventing C5-related diseases by using anti-C5 antibody covalenzumab |
WO2021024209A1 (en) | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Inc. | Antibodies that bind to pathological tau species and uses thereof |
CN114867751A (en) | 2019-08-12 | 2022-08-05 | 阿帕特夫研究和发展有限公司 | 4-1BB and OX40 binding proteins and related compositions and methods, anti-4-1 BB antibodies, anti-OX 40 antibodies |
WO2021042019A1 (en) | 2019-08-30 | 2021-03-04 | Agenus Inc. | Anti-cd96 antibodies and methods of use thereof |
TW202118512A (en) | 2019-09-12 | 2021-05-16 | 美商建南德克公司 | Compositions and methods of treating lupus nephritis |
TW202124444A (en) | 2019-09-16 | 2021-07-01 | 美商表面腫瘤學公司 | Anti-cd39 antibody compositions and methods |
TW202124446A (en) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | Combination therapies with entpd2 antibodies |
EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
EP4031579A2 (en) | 2019-09-18 | 2022-07-27 | F. Hoffmann-La Roche AG | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
EP4031575A1 (en) | 2019-09-19 | 2022-07-27 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
EP4031580A1 (en) | 2019-09-20 | 2022-07-27 | F. Hoffmann-La Roche AG | Dosing for anti-tryptase antibodies |
BR112022004302A2 (en) | 2019-09-25 | 2022-06-21 | Surface Oncology Inc | Anti-il-27 antibodies and uses thereof |
KR20220070237A (en) | 2019-09-27 | 2022-05-30 | 제넨테크, 인크. | Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies |
CA3156983A1 (en) | 2019-10-08 | 2021-04-15 | Nectin Therapeutics Ltd. | Antibodies against the poliovirus receptor (pvr) and uses thereof |
AU2020365836A1 (en) | 2019-10-18 | 2022-04-28 | F. Hoffmann-La Roche Ag | Methods of using anti-CD79b immunoconjugates to treat diffuse large B-cell lymphoma |
US11459389B2 (en) | 2019-10-24 | 2022-10-04 | Massachusetts Institute Of Technology | Monoclonal antibodies that bind human CD161 |
MX2022005132A (en) | 2019-11-04 | 2022-08-15 | Compugen Ltd | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies. |
EP4055388A1 (en) | 2019-11-06 | 2022-09-14 | Genentech, Inc. | Diagnostic and therapeutic methods for treatment of hematologic cancers |
WO2021110873A1 (en) | 2019-12-04 | 2021-06-10 | Medimmune Limited | Antibodies against lif and uses thereof |
EP4072682A1 (en) | 2019-12-09 | 2022-10-19 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Antibodies having specificity to her4 and uses thereof |
WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
CN113045655A (en) | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | anti-OX 40 antibodies and uses thereof |
US20230058982A1 (en) | 2019-12-27 | 2023-02-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-ctla-4 antibody and use thereof |
IL294330A (en) | 2020-01-06 | 2022-08-01 | Vaccinex Inc | Anti-ccr8 antibodies and uses thereof |
JP2023509195A (en) | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | How to treat pemphigus |
CN110818795B (en) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | anti-TIGIT antibodies and methods of use |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
CA3164559A1 (en) | 2020-01-31 | 2021-08-05 | Lars Mueller | Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine |
TW202144395A (en) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | Anti-CD137 antigen-binding molecule for use in cancer treatment |
WO2021173844A1 (en) | 2020-02-26 | 2021-09-02 | Biograph 55, Inc. | C19 c38 bispecific antibodies |
JP2023516945A (en) | 2020-02-28 | 2023-04-21 | 上海復宏漢霖生物技術股▲フン▼有限公司 | Anti-CD137 constructs and uses thereof |
JP2023516941A (en) | 2020-02-28 | 2023-04-21 | 上海復宏漢霖生物技術股▲フン▼有限公司 | Anti-CD137 constructs, multispecific antibodies and uses thereof |
WO2021175954A1 (en) | 2020-03-04 | 2021-09-10 | Imcheck Therapeutics Sas | Antibodies having specificity for btnl8 and uses thereof |
MX2022009597A (en) | 2020-03-06 | 2022-09-02 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate including novel cyclic dinucleotide derivative. |
JP2023516724A (en) | 2020-03-06 | 2023-04-20 | オーエヌエー セラピューティクス エセ.エレ. | Anti-CD36 antibodies and their use to treat cancer |
AU2021232853A1 (en) | 2020-03-10 | 2022-09-22 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
CR20220461A (en) | 2020-03-13 | 2022-10-21 | Genentech Inc | Anti-interleukin-33 antibodies and uses thereof |
TW202144417A (en) | 2020-03-13 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Pvrig binding protein and its medical uses |
CN117510630A (en) | 2020-03-19 | 2024-02-06 | 基因泰克公司 | Isotype selective anti-TGF-beta antibodies and methods of use |
US11365239B2 (en) | 2020-03-20 | 2022-06-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-SARS-COV-2 antibodies and uses thereof |
PE20230414A1 (en) | 2020-03-24 | 2023-03-07 | Genentech Inc | TIE2 FIXING AGENTS AND METHODS OF USE |
TW202202620A (en) | 2020-03-26 | 2022-01-16 | 美商建南德克公司 | Modified mammalian cells |
EP4126241A1 (en) | 2020-03-27 | 2023-02-08 | Novartis AG | Bispecific combination therapy for treating proliferative diseases and autoimmune disorders |
CN115397850A (en) | 2020-03-30 | 2022-11-25 | 豪夫迈·罗氏有限公司 | Antibodies that bind to VEGF and PDGF-B and methods of use thereof |
AR121706A1 (en) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES |
CA3170570A1 (en) | 2020-04-01 | 2021-10-07 | James J. KOBIE | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
WO2021202959A1 (en) | 2020-04-03 | 2021-10-07 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
EP4132971A1 (en) | 2020-04-09 | 2023-02-15 | Merck Sharp & Dohme LLC | Affinity matured anti-lap antibodies and uses thereof |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
KR20230005172A (en) | 2020-04-24 | 2023-01-09 | 에프. 호프만-라 로슈 아게 | Modulation of enzymes and pathways using sulfhydryl compounds and their derivatives |
MX2022013198A (en) | 2020-04-24 | 2022-11-14 | Genentech Inc | Methods of using anti-cd79b immunoconjugates. |
JP2023523450A (en) | 2020-04-28 | 2023-06-05 | ジェネンテック, インコーポレイテッド | Methods and compositions for non-small cell lung cancer immunotherapy |
WO2021222935A2 (en) | 2020-04-28 | 2021-11-04 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies and methods of use thereof |
US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
EP4143227A2 (en) | 2020-04-30 | 2023-03-08 | Sairopa B.V. | Anti-cd103 antibodies |
CN116963782A (en) | 2020-05-03 | 2023-10-27 | 联宁(苏州)生物制药有限公司 | Antibody drug conjugates comprising anti-TROP-2 antibodies |
KR20230029621A (en) | 2020-05-08 | 2023-03-03 | 알파인 이뮨 사이언시즈, 인코포레이티드 | APRIL and BAFF inhibitory immunomodulatory proteins with or without T cell inhibitory proteins and methods of use thereof |
JP2023525053A (en) | 2020-05-12 | 2023-06-14 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | A new method to treat cutaneous T-cell lymphoma and TFH-derived lymphoma |
AU2021275361A1 (en) | 2020-05-17 | 2023-01-19 | Astrazeneca Uk Limited | SARS-CoV-2 antibodies and methods of selecting and using the same |
WO2021234160A2 (en) | 2020-05-22 | 2021-11-25 | Formycon Ag | Ace2 fusion proteins and uses thereof |
US20230220057A1 (en) | 2020-05-27 | 2023-07-13 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing nerve growth factor and uses thereof |
BR112022024339A2 (en) | 2020-05-29 | 2022-12-27 | 23Andme Inc | ANTI CD200R1 ANTIBODIES AND METHODS OF THEIR USE |
CN116529260A (en) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | anti-CD 93 constructs and uses thereof |
MX2022015376A (en) | 2020-06-02 | 2023-04-14 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof. |
CN115697489A (en) | 2020-06-08 | 2023-02-03 | 豪夫迈·罗氏有限公司 | anti-HBV antibodies and methods of use thereof |
WO2021252977A1 (en) | 2020-06-12 | 2021-12-16 | Genentech, Inc. | Methods and compositions for cancer immunotherapy |
CA3181820A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
US20210395366A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
JP2023532234A (en) | 2020-06-22 | 2023-07-27 | イノベント バイオロジクス(スーチョウ)カンパニー,リミティド | Anti-CD73 antibody and its use |
JP2023531222A (en) | 2020-06-22 | 2023-07-21 | アルミラル・ソシエダッド・アノニマ | ANTI-IL-36 ANTIBODY AND METHODS OF USE THEREOF |
JP2023533217A (en) | 2020-06-24 | 2023-08-02 | ジェネンテック, インコーポレイテッド | Apoptosis resistant cell line |
PE20230840A1 (en) | 2020-06-25 | 2023-05-19 | Merck Sharp And Dohme Llc | HIGH AFFINITY ANTIBODIES DIRECTED TO PHOSPHORYLATED TAU AT SERINE 413 |
CR20230076A (en) | 2020-07-10 | 2023-03-13 | Hoffmann La Roche | Antibodies which bind to cancer cells and target radionuclides to said cells |
PE20231300A1 (en) | 2020-07-17 | 2023-08-24 | Genentech Inc | ANTI-NOTCH2 ANTIBODIES AND METHODS OF USE |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
MX2023001083A (en) | 2020-07-29 | 2023-04-10 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof. |
JP2023536602A (en) | 2020-08-03 | 2023-08-28 | ジェネンテック, インコーポレイテッド | Diagnostic and therapeutic methods for lymphoma |
CN116724236A (en) | 2020-08-06 | 2023-09-08 | 美国比奥维拉迪维股份有限公司 | Inflammatory cytokines and fatigue in subjects with complement-mediated diseases |
JP2023537078A (en) | 2020-08-10 | 2023-08-30 | アストラゼネカ・ユーケイ・リミテッド | SARS-CoV-2 Antibodies for Treating and Preventing COVID-19 |
EP4204092A1 (en) | 2020-08-25 | 2023-07-05 | Gilead Sciences, Inc. | Multi-specific antigen binding molecules targeting hiv and methods of use |
WO2022043517A2 (en) | 2020-08-27 | 2022-03-03 | Cureab Gmbh | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
TW202227625A (en) | 2020-08-28 | 2022-07-16 | 美商建南德克公司 | Crispr/cas9 multiplex knockout of host cell proteins |
PE20230986A1 (en) | 2020-09-04 | 2023-06-21 | Hoffmann La Roche | ANTIBODY THAT BINDS VEGF-A AND ANG2, AND METHODS OF USE |
EP4211165A1 (en) | 2020-09-14 | 2023-07-19 | Ichnos Sciences SA | Antibodies that bind to il1rap and uses thereof |
EP4225443A1 (en) | 2020-10-05 | 2023-08-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
AR123855A1 (en) | 2020-10-20 | 2023-01-18 | Genentech Inc | PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE |
TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
US20230400467A1 (en) | 2020-10-26 | 2023-12-14 | Compugen Ltd. | Pvrl2 and/or pvrig as biomarkers for treatment |
WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
CA3193930A1 (en) | 2020-10-29 | 2022-05-05 | Formycon Ag | Ace2 fusion proteins and uses thereof |
JP7402381B2 (en) | 2020-11-04 | 2023-12-20 | ジェネンテック, インコーポレイテッド | Administration for treatment with anti-CD20/anti-CD3 bispecific antibodies |
MX2023005131A (en) | 2020-11-04 | 2023-05-25 | Genentech Inc | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates. |
JP2023548878A (en) | 2020-11-04 | 2023-11-21 | ザ ロックフェラー ユニバーシティー | Neutralizing anti-SARS-COV-2 antibody |
TW202225191A (en) | 2020-11-04 | 2022-07-01 | 美商建南德克公司 | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
WO2022097061A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
EP4240765A2 (en) | 2020-11-06 | 2023-09-13 | Novartis AG | Antibody fc variants |
US20240025993A1 (en) | 2020-11-06 | 2024-01-25 | Novartis Ag | Cd19 binding molecules and uses thereof |
AU2021378152A1 (en) | 2020-11-11 | 2023-06-22 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY |
JP2023549925A (en) | 2020-11-24 | 2023-11-29 | ノバルティス アーゲー | Anti-CD48 antibodies, antibody-drug conjugates and uses thereof |
JP2023553808A (en) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | MCL-1 inhibitor antibody-drug conjugates and methods of use |
IL303328A (en) | 2020-12-01 | 2023-07-01 | Aptevo Res & Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies |
US20240052042A1 (en) | 2020-12-14 | 2024-02-15 | Novartis Ag | Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof |
CA3204702A1 (en) | 2020-12-17 | 2022-06-23 | F. Hoffmann-La Roche Ag | Anti-hla-g antibodies and use thereof |
JP2023554456A (en) | 2020-12-18 | 2023-12-27 | チューハイ トリノマブ ファーマシューティカル カンパニー リミテッド | Molecule that specifically binds to respiratory syncytial virus |
CN117098548A (en) | 2020-12-23 | 2023-11-21 | 信达生物制药(苏州)有限公司 | anti-B7-H3 antibodies and uses thereof |
WO2022140797A1 (en) | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines and uses thereof |
WO2022148732A1 (en) | 2021-01-06 | 2022-07-14 | F. Hoffmann-La Roche Ag | Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody |
WO2022152656A1 (en) | 2021-01-12 | 2022-07-21 | F. Hoffmann-La Roche Ag | Split antibodies which bind to cancer cells and target radionuclides to said cells |
KR20230131205A (en) | 2021-01-13 | 2023-09-12 | 에프. 호프만-라 로슈 아게 | combination therapy |
WO2022155324A1 (en) | 2021-01-15 | 2022-07-21 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
WO2022165275A2 (en) | 2021-01-28 | 2022-08-04 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies |
US20240082397A1 (en) | 2021-01-28 | 2024-03-14 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
TW202241454A (en) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | Novel method for producing antibody-immunostimulator conjugate |
JP2024509695A (en) | 2021-02-03 | 2024-03-05 | ジェネンテック, インコーポレイテッド | Multispecific binding proteolysis platform and methods of use |
AU2022224561A1 (en) | 2021-02-17 | 2023-09-28 | Dr. Falk Pharma Gmbh | Anti-cd30l antibodies and uses thereof |
EP4301781A1 (en) | 2021-03-01 | 2024-01-10 | Xilio Development, Inc. | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
EP4301467A1 (en) | 2021-03-01 | 2024-01-10 | Xilio Development, Inc. | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
JP2024509169A (en) | 2021-03-03 | 2024-02-29 | ソレント・セラピューティクス・インコーポレイテッド | Antibody-drug conjugates including anti-BCMA antibodies |
AU2022230745A1 (en) | 2021-03-03 | 2023-08-17 | Formycon Ag | Formulations of ace2 fc fusion proteins |
TW202302646A (en) | 2021-03-05 | 2023-01-16 | 美商當康生物科技有限公司 | Anti-vista constructs and uses thereof |
AU2022232951A1 (en) | 2021-03-10 | 2023-10-19 | Immunowake Inc. | Immunomodulatory molecules and uses thereof |
WO2022192647A1 (en) | 2021-03-12 | 2022-09-15 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
JP2024511970A (en) | 2021-03-15 | 2024-03-18 | ジェネンテック, インコーポレイテッド | Compositions and methods for the treatment of lupus nephritis |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
WO2022204724A1 (en) | 2021-03-25 | 2022-09-29 | Dynamicure Biotechnology Llc | Anti-igfbp7 constructs and uses thereof |
CN117241828A (en) | 2021-03-31 | 2023-12-15 | 美国比奥维拉迪维股份有限公司 | Reducing surgery-related hemolysis in patients with cold lectin disease |
EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
WO2022221720A1 (en) | 2021-04-16 | 2022-10-20 | Novartis Ag | Antibody drug conjugates and methods for making thereof |
IL307501A (en) | 2021-04-19 | 2023-12-01 | Hoffmann La Roche | Modified mammalian cells |
EP4334343A2 (en) | 2021-05-06 | 2024-03-13 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
AU2022270170A1 (en) | 2021-05-07 | 2023-09-21 | Surface Oncology, LLC | Anti-il-27 antibodies and uses thereof |
CA3216795A1 (en) | 2021-05-07 | 2022-11-10 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
TW202310876A (en) | 2021-05-12 | 2023-03-16 | 美商建南德克公司 | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
TW202306993A (en) | 2021-05-14 | 2023-02-16 | 美商建南德克公司 | Agonists of trem2 |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2022243261A1 (en) | 2021-05-19 | 2022-11-24 | F. Hoffmann-La Roche Ag | Agonistic cd40 antigen binding molecules targeting cea |
WO2022246259A1 (en) | 2021-05-21 | 2022-11-24 | Genentech, Inc. | Modified cells for the production of a recombinant product of interest |
EP4155321A1 (en) | 2021-06-04 | 2023-03-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-ddr2 antibodies and uses thereof |
IL309349A (en) | 2021-06-14 | 2024-02-01 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
WO2022266660A1 (en) | 2021-06-17 | 2022-12-22 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
TW202306989A (en) | 2021-06-22 | 2023-02-16 | 瑞士商諾華公司 | Bispecific antibodies for use in treatment of hidradenitis suppurativa |
CN117616123A (en) | 2021-06-25 | 2024-02-27 | 中外制药株式会社 | anti-CTLA-4 antibodies |
IL308633A (en) | 2021-06-25 | 2024-01-01 | Chugai Pharmaceutical Co Ltd | Use of anti-ctla-4 antibody |
WO2023275621A1 (en) | 2021-07-01 | 2023-01-05 | Compugen Ltd. | Anti-tigit and anti-pvrig in monotherapy and combination treatments |
KR20240028452A (en) | 2021-07-02 | 2024-03-05 | 제넨테크, 인크. | Methods and compositions for treating cancer |
TW202317633A (en) | 2021-07-08 | 2023-05-01 | 美商舒泰神(加州)生物科技有限公司 | Antibodies specifically recognizing tnfr2 and uses thereof |
TW202306985A (en) | 2021-07-12 | 2023-02-16 | 美商建南德克公司 | Structures for reducing antibody-lipase binding |
CN115812082A (en) | 2021-07-14 | 2023-03-17 | 舒泰神(北京)生物制药股份有限公司 | Antibody specifically recognizing CD40 and application thereof |
US20230049152A1 (en) | 2021-07-14 | 2023-02-16 | Genentech, Inc. | Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use |
CA3219606A1 (en) | 2021-07-22 | 2023-01-26 | F. Hoffmann-La Roche Ag | Heterodimeric fc domain antibodies |
WO2023004386A1 (en) | 2021-07-22 | 2023-01-26 | Genentech, Inc. | Brain targeting compositions and methods of use thereof |
WO2023010095A1 (en) | 2021-07-28 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating cancer |
AU2022320051A1 (en) | 2021-07-30 | 2024-01-25 | ONA Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
WO2023011338A1 (en) | 2021-08-02 | 2023-02-09 | 信达生物制药(苏州)有限公司 | Anti-cd79b×cd3 bispecific antibody and use thereof |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
US20230099756A1 (en) | 2021-08-07 | 2023-03-30 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
WO2023019239A1 (en) | 2021-08-13 | 2023-02-16 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
WO2023021055A1 (en) | 2021-08-19 | 2023-02-23 | F. Hoffmann-La Roche Ag | Multivalent anti-variant fc-region antibodies and methods of use |
TW202328177A (en) | 2021-08-27 | 2023-07-16 | 美商建南德克公司 | Methods of treating tau pathologies |
TW202325727A (en) | 2021-08-30 | 2023-07-01 | 美商建南德克公司 | Anti-polyubiquitin multispecific antibodies |
WO2023052541A1 (en) | 2021-09-30 | 2023-04-06 | Imcheck Therapeutics | Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
CA3232806A1 (en) | 2021-09-30 | 2023-04-06 | Seagen Inc. | B7-h4 antibody-drug conjugates for the treatment of cancer |
TW202321308A (en) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
WO2023064958A1 (en) | 2021-10-15 | 2023-04-20 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies |
TW202342095A (en) | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | Composition for treatment and prevention of covid-19 |
WO2023081818A1 (en) | 2021-11-05 | 2023-05-11 | American Diagnostics & Therapy, Llc (Adxrx) | Monoclonal antibodies against carcinoembryonic antigens, and their uses |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
TW202337494A (en) | 2021-11-16 | 2023-10-01 | 美商建南德克公司 | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
WO2023088959A1 (en) | 2021-11-16 | 2023-05-25 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
WO2023091968A1 (en) | 2021-11-17 | 2023-05-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
WO2023094507A1 (en) | 2021-11-24 | 2023-06-01 | Formycon Ag | Improved ace2 fusion proteins |
WO2023094571A1 (en) | 2021-11-25 | 2023-06-01 | Formycon Ag | Stabilization of ace2 fusion proteins |
TW202330582A (en) | 2021-12-15 | 2023-08-01 | 美商建南德克公司 | Stabilized il-18 polypeptides and uses thereof |
AR128031A1 (en) | 2021-12-20 | 2024-03-20 | F Hoffmann La Roche Ag | ANTI-LTBR AGONIST ANTIBODIES AND BISPECIFIC ANTIBODIES THAT COMPRISE THEM |
WO2023131901A1 (en) | 2022-01-07 | 2023-07-13 | Johnson & Johnson Enterprise Innovation Inc. | Materials and methods of il-1beta binding proteins |
WO2023139107A1 (en) | 2022-01-18 | 2023-07-27 | argenx BV | Galectin-10 antibodies |
WO2023141445A1 (en) | 2022-01-19 | 2023-07-27 | Genentech, Inc. | Anti-notch2 antibodies and conjugates and methods of use |
WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
WO2023168352A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
WO2023173026A1 (en) | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
US20240103010A1 (en) | 2022-03-18 | 2024-03-28 | Compugen Ltd. | Pvrl2 and/or pvrig as biomarkers for treatment |
WO2023178357A1 (en) | 2022-03-18 | 2023-09-21 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
WO2023186756A1 (en) | 2022-03-28 | 2023-10-05 | F. Hoffmann-La Roche Ag | Interferon gamma variants and antigen binding molecules comprising these |
WO2023187657A1 (en) | 2022-03-30 | 2023-10-05 | Novartis Ag | Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023201299A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
WO2023209177A1 (en) | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
WO2023215737A1 (en) | 2022-05-03 | 2023-11-09 | Genentech, Inc. | Anti-ly6e antibodies, immunoconjugates, and uses thereof |
TW202400638A (en) | 2022-05-10 | 2024-01-01 | 法商感應檢查療法公司 | Anti-btn3a antibodies for use in methods of treating gastro-intestinal inflammatory disorders |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
TW202402810A (en) | 2022-05-11 | 2024-01-16 | 瑞士商赫孚孟拉羅股份公司 | Antibody that binds to vegf-a and il6 and methods of use |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023239803A1 (en) | 2022-06-08 | 2023-12-14 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
US20230406942A1 (en) | 2022-06-10 | 2023-12-21 | Horizon Therapeutics Ireland Dac | Igf1r antibodies |
WO2023242361A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | Fcrn binding molecules and methods of use |
US20240117021A1 (en) | 2022-06-15 | 2024-04-11 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
WO2023250507A1 (en) | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020407A1 (en) | 2022-07-19 | 2024-01-25 | Staidson Biopharma Inc. | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024020579A1 (en) | 2022-07-22 | 2024-01-25 | Bristol-Myers Squibb Company | Antibodies binding to human pad4 and uses thereof |
WO2024026496A1 (en) | 2022-07-28 | 2024-02-01 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies |
WO2024028732A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
WO2024028731A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Transferrin receptor binding proteins for treating brain tumors |
WO2024037633A2 (en) | 2022-08-19 | 2024-02-22 | Evive Biotechnology (Shanghai) Ltd | Formulations comprising g-csf and uses thereof |
WO2024044675A1 (en) | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies |
WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
WO2024054929A1 (en) | 2022-09-07 | 2024-03-14 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
WO2024052503A1 (en) | 2022-09-08 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to ltbp2 and uses thereof |
-
1994
- 1994-06-15 WO PCT/GB1994/001290 patent/WO1994029351A2/en not_active Application Discontinuation
- 1994-06-15 JP JP7501518A patent/JPH08511420A/en active Pending
- 1994-06-15 CA CA 2163345 patent/CA2163345A1/en not_active Abandoned
- 1994-06-15 EP EP94917750A patent/EP0714409A1/en not_active Withdrawn
- 1994-06-15 AU AU69341/94A patent/AU691811B2/en not_active Ceased
Non-Patent Citations (8)
Title |
---|
ALEGRE M.-L. ET AL.: "Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody", JOURNAL OF IMMUNOLOGY, vol. 148, June 1992 (1992-06-01), BALTIMORE US, pages 3461 - 3468 * |
CHAPPEL M. S. ET AL.: "Identification of the Fcgamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 88, October 1991 (1991-10-01), WASHINGTON US, pages 9036 - 9040 * |
DUNCAN A.R. ET AL.: "The binding site for C1q on IgG", NATURE, vol. 332, 1988, LONDON GB, pages 738 - 740 * |
GREENWOOD J. ET AL.: "Structural motifs involved in human IgG antibody effector functions", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 23, 1993, pages 1098 - 1104 * |
JOLIFFE L. K.: "Humanized antibodies: enhancing therapeutic utility through antibody engineering", INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 10, June 1993 (1993-06-01), LONDON GB, pages 241 - 250 * |
LAMPSON L. A. ET AL.: "Two populationS of Ia-like molecules on a human B cell line", JOURNAL OF IMMUNOLOGY, vol. 125, 1980, BALTIMORE US, pages 293 - 299 * |
NOSE M. ET AL.: "Biological significance of carbohydrate chains on monoclonal antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 80, 1983, WASHINGTON US, pages 6632 - 6636 * |
TAO M.-H. ET AL.: "The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal seqence of the Ch2 domain", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 173, no. 4, April 1991 (1991-04-01), pages 1025 - 1028 * |
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124731B2 (en) | 2002-03-01 | 2012-02-28 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8734791B2 (en) | 2002-03-01 | 2014-05-27 | Xencor, Inc. | Optimized fc variants and methods for their generation |
US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8986686B2 (en) | 2002-06-14 | 2015-03-24 | Medimmune, Llc | Stabilized liquid anti-RSV antibody formulations |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8809503B2 (en) | 2002-09-27 | 2014-08-19 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8858937B2 (en) | 2002-09-27 | 2014-10-14 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US9193798B2 (en) | 2002-09-27 | 2015-11-24 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8039592B2 (en) | 2002-09-27 | 2011-10-18 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US8093359B2 (en) | 2002-09-27 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8383109B2 (en) | 2002-09-27 | 2013-02-26 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US9353187B2 (en) | 2002-09-27 | 2016-05-31 | Xencor, Inc. | Optimized FC variants and methods for their generation |
US8951517B2 (en) | 2003-01-09 | 2015-02-10 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8735545B2 (en) | 2003-03-03 | 2014-05-27 | Xencor, Inc. | Fc variants having increased affinity for fcyrllc |
US8779100B2 (en) | 2004-09-03 | 2014-07-15 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8852586B2 (en) | 2004-11-12 | 2014-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8338574B2 (en) | 2004-11-12 | 2012-12-25 | Xencor, Inc. | FC variants with altered binding to FCRN |
US8883973B2 (en) | 2004-11-12 | 2014-11-11 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8324351B2 (en) | 2004-11-12 | 2012-12-04 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9040041B2 (en) | 2005-10-03 | 2015-05-26 | Xencor, Inc. | Modified FC molecules |
US9574006B2 (en) | 2005-10-06 | 2017-02-21 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US8957187B2 (en) | 2005-12-02 | 2015-02-17 | Genentech, Inc. | Binding polypeptides and uses thereof |
US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
US9555087B2 (en) | 2007-09-04 | 2017-01-31 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9107862B2 (en) | 2007-09-04 | 2015-08-18 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9375466B2 (en) | 2007-09-04 | 2016-06-28 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9243069B2 (en) | 2008-04-02 | 2016-01-26 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using the same |
US8993730B2 (en) | 2008-04-02 | 2015-03-31 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
US9469692B2 (en) | 2008-04-02 | 2016-10-18 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using same |
US8410250B2 (en) | 2009-03-25 | 2013-04-02 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
US8710189B2 (en) | 2009-03-25 | 2014-04-29 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
US9283274B2 (en) | 2009-10-06 | 2016-03-15 | Medimmune Limited | RSV specific binding molecule |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
US9266948B2 (en) | 2009-12-23 | 2016-02-23 | Genentech, Inc. | Anti-Bv8 antibodies and uses thereof |
US9475881B2 (en) | 2010-01-19 | 2016-10-25 | Xencor, Inc. | Antibody variants with enhanced complement activity |
US9441049B2 (en) | 2010-03-04 | 2016-09-13 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9011852B2 (en) | 2010-04-30 | 2015-04-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
US8771966B2 (en) | 2010-06-03 | 2014-07-08 | Genentech, Inc. | Immuno-PET imaging of antibodies and immunoconjugates and uses therefor |
US9133273B2 (en) | 2010-11-19 | 2015-09-15 | Eisai R&D Management Co., Ltd. | Nucleic acids encoding neutralizing anti-CCL20 antibodies |
US8969526B2 (en) | 2011-03-29 | 2015-03-03 | Roche Glycart Ag | Antibody Fc variants |
US9428574B2 (en) | 2011-06-30 | 2016-08-30 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
US9266961B2 (en) | 2012-06-15 | 2016-02-23 | Genentech, Inc. | Anti-PCSK9 antibodies, formulations, dosing, and methods of use |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
EP4342529A2 (en) | 2015-12-18 | 2024-03-27 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
US11958903B2 (en) | 2019-03-29 | 2024-04-16 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JPH08511420A (en) | 1996-12-03 |
EP0714409A1 (en) | 1996-06-05 |
AU691811B2 (en) | 1998-05-28 |
CA2163345A1 (en) | 1994-12-22 |
AU6934194A (en) | 1995-01-03 |
WO1994029351A2 (en) | 1994-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994029351A3 (en) | Antibodies | |
AU4472793A (en) | Methods for diagnosis and therapy using defined regions of the T cell antigen receptor | |
IL90990A0 (en) | Pharmaceutical and diagnostic compositions containing monoclonal antibodies reactive with cachectin and a cell for the production thereof | |
AU7272291A (en) | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent | |
AU588806B2 (en) | Drug, and methods of preparing and using it for treatment of tumors | |
WO1998022136A3 (en) | Stable lyophilized pharmaceutical substances from monoclonal or polyclonal antibodies | |
DE2963977D1 (en) | Antigen preparation, process for producing it and pharmacological or dental preparations containing the antigen preparation or antibodies thereto | |
CA2212058A1 (en) | Preparation and use of a specific gaba-a.alpha.5 receptor ligand for treatment of alzheimer's disease | |
WO1997008318A3 (en) | Compounds and methods for treatment and diagnosis of prostate cancer | |
AU6785987A (en) | Selecting and testing antibodies for cancer therapy | |
SI0771788T1 (en) | Substituted sulphonimidamides, method for their preparation, their use as medicament or diagnostic and medicament containing them | |
EP0147146A3 (en) | Enhancement of transdermal drug delivery | |
AU1347688A (en) | Viral antigen, process for its production, and application in diagnosis and therapy (vaccine) | |
IL81370A (en) | Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions | |
EP0200169A3 (en) | Pharmaceutical composition for cure and prevention of cardiovascular disease and method of preparing the same | |
EP0194851A3 (en) | Human tumor therapy | |
ES8704082A1 (en) | Tumour therapeutic agent and process for its preparation. | |
MY113431A (en) | Substituted benzenesulfonylureas and -thioureas, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | |
AU591901B2 (en) | Process for the in vitro immunization of human splenocytes against tumor associated antigens | |
IE860227L (en) | Monoclonal anti-alpha-amylase antibody | |
AU569354B2 (en) | (-)-1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane | |
AU3806285A (en) | Hydantoin derivatives, process for producing the same and medicine containing the same. | |
JPS5615215A (en) | Preparation of human immunoglobulin for intravenous injection with immobilized pepsin gel | |
AU4081085A (en) | Process for preparing glycosidic linkage related antigen | |
HU9601139D0 (en) | Metal-bonding cystein-free peptides for diagnosis and therapy, process for producing them and pharmaceutical preparations containing these compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2163345 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994917750 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1996 564250 Country of ref document: US Date of ref document: 19960212 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1994917750 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994917750 Country of ref document: EP |